WO1996032118A1 - Use of nitric oxide-releasing agents to treat impotency - Google Patents

Use of nitric oxide-releasing agents to treat impotency Download PDF

Info

Publication number
WO1996032118A1
WO1996032118A1 PCT/US1996/004889 US9604889W WO9632118A1 WO 1996032118 A1 WO1996032118 A1 WO 1996032118A1 US 9604889 W US9604889 W US 9604889W WO 9632118 A1 WO9632118 A1 WO 9632118A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
nitric oxide
chain alkyl
branched chain
compound
Prior art date
Application number
PCT/US1996/004889
Other languages
French (fr)
Inventor
Larry K. Keefer
Joseph E. Saavedra
Paul C. Doherty
Mark S. Hanamoto
Virgil A. Place
Original Assignee
The United States Of America, Represented By The Secretary, Department Of Health And Human Services
Vivus, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, Represented By The Secretary, Department Of Health And Human Services, Vivus, Inc. filed Critical The United States Of America, Represented By The Secretary, Department Of Health And Human Services
Priority to PL96322742A priority Critical patent/PL322742A1/en
Priority to JP8531124A priority patent/JPH11508872A/en
Priority to EP96911665A priority patent/EP0820294A1/en
Priority to AU54480/96A priority patent/AU5448096A/en
Publication of WO1996032118A1 publication Critical patent/WO1996032118A1/en
Priority to NO974680A priority patent/NO974680L/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00Chemical modification by after-treatment
    • C08F8/30Introducing nitrogen atoms or nitrogen-containing groups
    • C08F8/32Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines

Definitions

  • the present invention relates to a method of treating impotency in a male, and more particularly, to the use of certain nitric oxide-releasing agents to treat impotency.
  • the present invention also relates to nitric oxide delivery means comprising nitric oxide- releasing agents for use in the method.
  • Penile erection and detumescence involve a complex interaction of direct neuronal activation combined with the release of endothelial derived contractile and relaxant factors.
  • a variety of neurotransmitter substances and vasoactive modulators have been described. Of these, nitric oxide appears to play a primary role in the development of an erection.
  • Cavernosal smooth muscle relaxation is one of the primary events in penile erection. Although it is believed to be initiated by the synthesis and release of NO from nonadrenergic-noncholinergic neurons of the corpus cavemosum (Kimura et al., Nippon Hinyokika Gakkai Zasshi 84(9): 1660-1664 (1993); Rajfer et al. , N. Engl. J. Med. 326(2): 90-94 (1992); Knispel et al., Urol. Res. 20(4): 253-257 (1992); Burnett et al., Science 257(5068): 401-403 (1992); and Mills et al. , Biol. Reprod.
  • therapies for erectile dysfunction include needle injection of a vasodilator drugs directly into the penis; a vacuum constriction device (VCD) , which pulls blood into the penis and holds it there with a constriction ring; a surgical implant, which provides rigidity; oral medication, such as yohimbine, which appears to have beneficial effects in only a small proportion of patients; psychological therapy, for which few data exist on long term benefit; and vascular surgery, which is appropriate in only a very small number of patients. All six therapies have significant drawbacks. In fact, they are so limited in appeal that fewer than ten percent of men with erectile dysfunction have adopted any one of the therapies at all. In addition, each of these therapies suffers from exceedingly high rates of discontinuance for reasons that are not entirely related to the therapy, itself. There remains a need, therefore, for an effective method of treating impotency.
  • Nitric oxide has been utilized as a means of studying penile erection and penile dysfunction due to diabetes and venous leakage, for example.
  • the potential usefulness of nitric oxide to treat impotence has been discussed by McGuffey (Am. Pharm. NS33(7): 20 (1993)).
  • Nitric oxide in its pure form is a highly reactive gas having limited solubility in aqueous media (WHO Task Group on Environmental Health Criteria for Oxides of Nitrogen, Oxides of Nitrogen. Environmental Health Criteria 4 (World Health Organization: Geneva, 1977)). Nitric oxide, therefore, is difficult to introduce reliably into most biological systems without premature decomposition.
  • a number of compounds have been developed that are capable of delivering nitric oxide in a pharmacologically useful way. Such compounds include compounds that release nitric oxide upon being metabolized and compounds that release nitric oxide spontaneously in aqueous solution.
  • S-Nitroso-N- acetylpenicillamine has been reported to release nitric oxide in solution and to be effective at inhibiting DNA synthesis (Garg et al., Biochem. and BioPhvs. Res. Co m.. HI, 474-479 (1990)).
  • SNP has been administered to primates for purposes of studying the physiology and pharmacology of erection (Hellstro et al., J. Urol. 151(60: 1723-1727 (1994)). Intracavernosal injection of SNP induced erections with dose-dependent increases in cavernosal pressure and penile length.
  • the NO donor linsidomine chlorohydrate, otherwise known as 3-morpholinosydnonimine or SIN-1 was administered to 30 human patients with erectile dysfunction caused by venous leakage (Wegner et al. , Urology 42(4): 409-411 (1993)) and was less effective than prostaglandin El (PGEl) in treating the dysfunction in over two-thirds of the patients treated.
  • PEP prostaglandin El
  • SIN-1 was also found to be less effective than SNP in relaxing isolated rabbit corpus cavemosum (Holmquist et al., J. Urol. 150(4): 1310-1315 (1993)). More promising results with SIN-1 were obtained in a 63-patient study carried out by Stief et al. (J. Urol. 148(5): 1437-1440 (1992)).
  • activation of SIN-l by oxygen produces both NO and superoxide ion, two species that can combine with one another to produce the potent oxidant, ONOO " .
  • the potential to produce this toxic by-product is believed to limit the utility of such sydnonimine drugs.
  • nitric oxide-nucleophile complexes Numerous nitric oxide-nucleophile complexes also have been described, e.g., by Drago, ACS Adv. Chem. Ser.. 3_6_, 143-149 (1962). See also Longhi and Drago, Inor . Chem.. Z, 85 (1963). Some of these complexes, known as NONOates, evolve nitric oxide on heating or hydrolysis (Maragos et al., J. Med. Chem.. 34. 3242-3247 (1991)) .
  • NONOates having reproducible half- lives ranging from 2 seconds to 20 hours have been prepared. They can be O-alkylated to provide either spontaneous NO-generators with half-lives of up to a week or more or prodrugs that cannot release NO at all until the oxygen substituent is removed etabolically.
  • the NONOate function can be coordinated via the two oxygen atoms to metal centers; it can be attached to natural products, such as sper ine (a constituent of human semen) and peptides; and it can be bound in solid polymeric matrices to provide a point source of NO.
  • a compound containing more than one nucleophile residue (such as, for example, the polya ine, sper ine) can be bound to more than one NONOate group, to thereby provide a single NONOate molecule with bi-or polyphasic NO release rates.
  • the NONOates constitute a most advantageous series of compounds on which to base NO donor drug development efforts.
  • Nitric oxide/nucleophile complexes that release nitric oxide in aqueous solution are disclosed in U.S. Patent Nos. 4,954,526, 5,039,705, 5,155,137,
  • nitric oxide/nucleophile complexes can be incorporated into polymers in order to overcome this limitation by enabling concentrated and localized release of NO at a given site in a controllable and predictable manner such that effective dosing can be realized. This imparts a tremendous advantage to the technology for the treatment of erectile dysfunction.
  • the present invention provides a method of treatment for impotency in a male animal that overcomes the above-described disadvantages of currently available treatment methods by employing NONOates as nitric oxide- releasing agents in the form of polymers, pharmaceutical compositions, and various delivery means comprising such compositions and polymers. Accordingly, the present invention also seeks to provide delivery means for use in the present inventive method.
  • the present invention provides a method of treatment for impotency in a male animal, including a human.
  • the method comprises the administration of a nitric oxide-releasing agent, which is capable of providing a penile erection-inducing amount of nitric oxide to the male animal and which includes a nitric oxide-releasing [N 2 0 2 ] functional group.
  • the nitric oxide-releasing agent can be a compound comprising a nitric oxide-releasing [N 2 0 2 ] functional group, it can be a polymer to which is bound a nitric oxide-releasing
  • the nitric oxide-releasing agent provides NO to the penis of an impotent male animal in an amount sufficient to cause a penile erection.
  • the delivery means can be coated with or made of a nitric oxide-releasing agent in the form of a polymer and enables the controllable and predictable release of NO to the penis in such a manner that effective therapeutic dosing of impotency is realized.
  • the delivery means can be biodegradable. Delivery means comprising the nitric oxide-releasing agent are also provided. Brief Description of the Drawings Figure 1 illustrates an exploded view of one embodiment of a transurethral therapeutic device for delivery of the nitric oxide-releasing agent to the urethra.
  • Figure 2 is a graph of corporal pressure (mm Hg) versus dose ( ⁇ g/200 ⁇ l) .
  • Figure 3 is a graph of penile length change versus dose ( ⁇ g/200 ⁇ l) .
  • the present invention provides a method for the treatment of impotency in a male animal, including a human.
  • the method involves the administration to a male animal, in particular a human, of a nitric oxide- releasing agent.
  • the nitric oxide-releasing agent can be a compound comprising a nitric oxide-releasing [N 2 0 2 ] functional group or a polymer to which is bound a nitric oxide-releasing [N 2 0 2 ] functional group or a delivery means, such as a transurethral applicator, a penile implant, a dermal patch or a condom, comprising such a compound or polymer.
  • “Bound to a polymer” means that the [N 2 0 2 ] functional group is associated with, part of, incorporated with or contained within the polymeric matrix either physically or chemically. Physical association or bonding of the N 2 0 2 " functional group to the polymer may be achieved by coprecipitation of the polymer with a nitric oxide/nucleophile complex as well as by covalent bonding of the N 2 0 2 " group to the polymer.
  • Chemical bonding of the N 2 0 2 " functional group to the polymer may be by, for example, covalent bonding of the nucleophile moiety of the nitric oxide/nucleophile adduct to the polymer such that the nucleophile residue to which the N 2 0 2 " group is attached forms part of the polymer itself, i.e., is in the polymer backbone or is attached to pendant groups on the polymer backbone.
  • the manner in which the nitric oxide-releasing N 2 0 2 " functional group is associated, part of, or incorporated with or contained within, i.e., "bound,” to the polymer is inconsequential to the present invention and all means of association, incorporation and bonding are contemplated herein.
  • the delivery means can be coated with or made of a nitric oxide-releasing agent in the form of a polymer and enables the controllable and predictable release of NO to the penis in such a manner that effective therapeutic dosing of impotency is realized.
  • a nitric oxide-releasing agent in the form of a polymer and enables the controllable and predictable release of NO to the penis in such a manner that effective therapeutic dosing of impotency is realized.
  • “Nitric oxide delivery means” is meant to include the many forms in which the nitric oxide-releasing agent can be configured, such as a transurethral applicator, an implant, drug pump, catheter, self-adhering means, liposome, microparticle, solution, microsphere, bead, disk or other pharmaceutical composition as described more fully below.
  • the delivery means can be biodegradable.
  • the nitric oxide-releasing agent provides NO to the penis of an impotent male animal in an amount sufficient to cause a penile erection. Determination of what amount is sufficient to induce a penile erection is as described below with respect to dosages. Whether or not a particular animal suffers from impotency is readily determined. Whether or not a particular animal is at risk for impotency can be assessed by those of skill in the art by taking into account known risk factors. Factors such as diabetes mellitus or venous leakage are likely to place a man at risk for impotency.
  • the present invention also provides various nitric oxide delivery means for use in the present inventive method as described more fully below.
  • the nitric oxide-releasing [N 2 0 2 ] functional group is X N(0)N0] or [N(0)NO- ⁇ -X, wherein X is an organic or inorganic moiety bonded to the - N(0)NO] or [N(O) on ⁇ functional group.
  • the compound containing the [N 2 0 2 ] functional group can be incorporated into or be part of a polymer.
  • the [N 2 0 2 ] group can be covalentiy bonded in the polymer by way of the moiety X. Incorporation of the N 0 2 " functional group into a polymer enables localized release of NO to the penis. "Localized release" means into or adjacent to the corpus cavemosum.
  • Localized release enhances the selectivity of action of the nitric oxide-releasing [N 2 0 2 ] functional group. If [N 2 0 2 ] functional groups attached to the polymer are localized, then the effect of their NO release will be concentrated in the tissues with which they are in contact. If the polymer is soluble, selectivity of action can still be arranged, for example, by attachment to or derivatization of an antibody specific to the target tissue. Similarly, attachment of [N 2 0 ] functional groups to small peptides that mimic the recognition sequences of ligands for important receptors provides localized, concentrated NO release, as would attachment to oligonucleotides capable of site-specific interactions with target sequences in a nucleic acid.
  • incorporation of the [N 2 0 2 ] functional group into a polymer can reduce the propensity of the nitric oxide/nucleophile adduct for the relatively rapid release of NO. This prolongs the release of NO by the [N 2 0 2J functional group, and allows for efficient dosing to achieve a penile erection and, possibly, concomitant reduction in the frequency of dosing.
  • N 2 0 2 groups near the surface of the particle should be available for rapid release while those that are more deeply imbedded are sterically shielded, requiring more time and/or energy for the nitric oxide to work its way into the medium.
  • increasing positive charge in the vicinity of an N 2 0 2 ⁇ functional group also tends to increase the halflife of nitric oxide generation.
  • the mechanism of this rate retardation may be attributable simply to repulsive electrostatic interactions, i.e., increasing the number of H + -repelling positive charges in the vicinity of the N 2 0 2 " groups inhibits attack of positively charged H + ions on the N 2 0 2 " functional group and slows the rate of its H + - catalyzed decomposition.
  • partially converted structures can be produced on less- than-exhaustive treatment with nitric oxide that after exposure to water contain a large number of positively charged ammonium centers surrounding the N 2 0 2 ⁇ group that electrostatically inhibit the approach of H + ions capable of initiating nitric oxide loss from the nitric oxide releasing N 2 0 2 " functional group.
  • nitric oxide-releasing [N 0 2 ] functional groups that are bound to the polymer generally are capable of releasing NO in an aqueous environment spontaneously upon contacting an aqueous environment, i.e., they do not require activation through a redox reaction or electron transfer, such as is required for glyceryl trinitrate and SNP.
  • Some of the nitric oxide/nucleophile complexes useful in the context of the present invention do require activation by particular means, but only as necessary to free the nitric oxide- releasing X-£-N(0)NO] ⁇ group in the vicinity of the penis or corpus cavemosum.
  • covalent attachment of a protecting group to the anionic [N(0)N0] ⁇ function provides a means of postponing NO release until the molecule reaches the penis, where cells/tissues are capable of metabolically removing the protecting group.
  • the polymer-bound, nitric oxide-releasing compositions of the present invention are capable of releasing NO in an aqueous solution, such a polymer preferably releases NO under physiological conditions.
  • the nitric oxide-releasing [N 2 0 2 ] functional group is preferably a nitric oxide/nucleophile adduct, i.e., a complex of NO and a nucleophile, most preferably a nitric oxide/nucleophile complex which contains the anionic moiety X N(0)N0] " , wherein X is any suitable nucleophile residue.
  • nitric oxide/nucleophile complexes are stable solids and are capable of delivering NO in a biologically usable form at a predictable rate.
  • nitric oxide/nucleophile complexes include those having the following formulas:
  • J is an organic or inorganic moiety, including, for example, a moiety which is not linked to the nitrogen of the [N 2 0 2 ] group through a carbon atom
  • M* x is a pharmaceutically acceptable cation, where x is the valence of the cation, a is 1 or 2, and b and c are the smallest integers that result in a neutral compound, preferably such that the compound is not a salt of alanosine or dopastin, as described in U.S. Patent No. 5,212,204, incorporated herein by reference;
  • R 1; R 2 , R 3 , R 4 , and R 5 are the same or different and may be hydrogen, C 3 _ 8 cycloalkyl, C 1-12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, and x, y, and z are the same or different and are integers from 2 to 12, as described in U.S. Patent No. 5,155,137, incorporated herein by reference;
  • B is or —N N— 2 0 2 ⁇ ,
  • R 6 and R 7 are the same or different and may be hydrogen, 3 - 8 cycloalkyl, C 1 _ 12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-trichloro- t-butoxycarbonyl, f is an integer from 0 to 12, with the proviso that when B is the substituted piperazine moiety — N N-N 2 0 2 "
  • f is an integer from 2 to 12, as described in U.S, Patent 5,250,550 incorporated herein by reference;
  • R 8 is hydrogen, C 3 _ 8 cycloalkyl, C 1-12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-tri-chloro-t-butoxycarbonyl
  • R 9 is hydrogen or a C 1 -C 12 straight or branched chain alkyl, and g is 2 to 6, as described in U.S. Patent No. 5,250,550, incorporated herein by reference;
  • R-* ⁇ and R 2 are independently selected from the group consisting of a straight chain or branched chain l ⁇ C 12 a ⁇ k yl group and a benzyl group, preferably such that no branch occurs on the alpha carbon atom, or else R ⁇ and R 2 , together with the nitrogen atom to which they are bonded, form a heterocyclic group, preferably a pyrrolidino, piperidino, piperazino or morpholino group, M +x is a pharmaceutically acceptable cation, and x is the valence of the cation, as described in U.S. Patent Nos. 5,039,705 and 5,208,233 and U.S. patent application Serial No. 08/017,270, filed February 12, 1993, and incorporated herein by reference; K [ (M) x ⁇ ' ( L) y (R 1 R 2 N-N 2 0 2 ) z ] (VI )
  • M is a pharmaceutically acceptable metal, or, where x is at least two, a mixture of two different pharmaceutically acceptable metals, L is a ligand different from (R 1 R 2 N-N 2 0 2 ) and is bound to at least one metal, R 1 and R 2 are each organic moieties and may be the same or different (preferably where M is copper, x is one, L is methanol, and y is one, that at least one of R 1 or R 2 is not ethyl) , x is an integer of from 1 to 10, x' is the formal oxidation state of the metal M, and is an integer of from 1 to 6, y is an integer of from 1 to 18, and where y is at least 2, the ligands L may be the same or different, z is an integer of from 1 to 20, and K is a pharmaceutically acceptable counterion to render the compound neutral to the extent necessary, as described in U.S. Patent 5,389,675 and incorporated herein by reference; [R-N(H)N(NO)
  • R is C _ 8 lower alkyl, phenyl, benzyl, or C 3 _ 8 cycoloalkyl, any of which R groups may be substituted by one to three substituents, which are the same or different, selected from the group consisting of halo, hydroxy, C ⁇ g alkoxy, -NH 2 , -C(0)NH 2 , -CH(O) , -C(0)OH, and -N0 2
  • X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from the group consisting of C 1 _ 8 lower alkyl, -C(0)CH 3 , and -C(0)NH 2
  • y is one to three, consistent with the valence of X, as described in U.S. Patent No. 4,954,526 and incorporated herein by reference; and
  • R ⁇ and R 2 are independently chosen from C j ., straight chain alkyl, C 1 _ 12 alkoxy or acyloxy substituted straight chain alkyl, C 2 _ 12 hydroxy or halo substituted straight chain alkyl, C 3 _ 12 branched chain alkyl, C 3 _ 12 hydroxy, halo, alkoxy, or acyloxy substituted branched chain alkyl, C 3 _ 12 straight chain olefinic and C 3 _ 12 branched chain olefinic which are unsubstituted or substituted with hydroxy, alkoxy, acyloxy, halo or benzyl, or ⁇ 1 and R 2 , together with the nitrogen atom to which they are bonded, form a heterocyclic group, preferably a pyrrolidino, piperidino, piperazino or morpholino group, and R 3 is a group selected from C 1-1 straight chain and C 3 _ 12 branched chain alkyl which are un
  • polymers suitable for use in the present invention are polyolefins, such as polystyrene, polypropylene, polyethylene, polytetrafluorethylene, polyvinylidene difluoride, polyvinylchloride, polyethyleneimine, and derivatives thereof; polyethers, such as polyethyleneglycol; polyesters, such as poly(lactide/glycolide) ; polyamides, such as nylon; polyurethanes; starburst dendimers biopolymers, such as peptides or proteins (e.g., antibodies), nucleic acids (e.g., oligonucleotides), and the like.
  • the physical and structural characteristics of the polymers suitable for use in the present invention are not narrowly critical, but rather will depend on the route and frequency of administration.
  • the polymer can be biodegradable.
  • nitric oxide-releasing agents can be administered in a wide variety of forms of delivery means. Any delivery means should adequately protect the integrity of the NO prior to its release and should control the release of the NO at such a rate, in such an amount, and in such a location as to serve as an effective means of treating the impotency.
  • delivery means for local administration or administration for localized release include, but are not limited to, a penile implant, a drug pump, a drug- delivery catheter (pressure-driven, iontophoretic or transurethral) , a self-adhering means, a liposoroe, a microparticle, a microsphere, a bead, a condom, a dermal patch, a disk or other device.
  • the advantages of local administration or localized release include the ability to attain effective concentrations of NO at the target site more quickly, the use of a smaller dose, and the realization of fewer toxic side effects than could occur on systemic administration and release.
  • Delivery means for systemic administration for localized release include, but are not limited to, solutions, suspensions, emulsions, capsules, sachets, tablets, dermal (topical) patches, lozenges, aerosols, liposomes, microparticles, microspheres, beads, prodrugs, tissue-specific antibodies, small peptides that mimic ligand recognition sequences, and sequence-specific oligonucleotides as described above.
  • the polymer, itself, may be structurally sufficient to serve as a form of delivery means.
  • the polymer can be incorporated into or coated onto other matrices, substrates or the like, or can be microencapsulated or the like.
  • the nitric oxide-releasing [N 2 0 2 ] functional groups can be bound to a polymeric support in a number of different ways.
  • the compounds described above can be bound to the polymer by coprecipitation of such compounds with the polymer. Coprecipitation can involve, for example, solubilizing both the polymer and the nitric oxide/nucleophile compound and evaporating the solvent.
  • Monomers containing the [N 0 2 ] group also can be dissolved in molten polymer, which, upon solidification when the temperature is lowered, contains a rather uniform distribution of [N 2 0 2 ] groups within the matrix.
  • the [N 0 ] functional group can be attached to an atom in the backbone of the polymer, or it can be attached to a group pendant to the polymer backbone, or it can simply be entrapped in the polymeric matrix.
  • the polymer includes, in its backbone, sites that are capable of reacting with NO to bind the NO for future release.
  • the polymer is polyethyleneimine
  • the polymer includes nucleophilic nitrogen atoms, which react with NO to form the [N 2 0 2 ] functional group at the nitrogen in the backbone.
  • the polymer can contain, or be derivatized with, a suitable nucleophilic residue capable of reacting with NO to form the [N 2 0 2 ] functionality. Reaction of the polymer that contains a suitable nucleophilic residue, or of the suitably derivatized polymer, with NO thus provides a polymer- bound nitric oxide-releasing [N 2 0 2 ] functional group.
  • nitric oxide- releasing agents of the present invention suitable methods of administering the nitric oxide- releasing agents of the present invention to a male animal, including a human male, are available, and, although more than one route can be used to administer a particular compound or polymer, a particular route can provide a more immediate and more effective result than another route.
  • Pharmaceutically acceptable carriers are also well-known to those who are skilled in the art. The choice of carrier for a pharmaceutical composition will be determined in part by the particular composition, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions for use in the present invention.
  • Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the polymer-bound composition dissolved in diluents, such as water or saline, (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solids or granules, (c) suspensions in an appropriate liquid, and (d) suitable emulsions.
  • liquid solutions such as an effective amount of the polymer-bound composition dissolved in diluents, such as water or saline
  • diluents such as water or saline
  • capsules, sachets or tablets each containing a predetermined amount of the active ingredient, as solids or granules
  • suspensions in an appropriate liquid and (d) suitable emulsions.
  • Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers.
  • Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addit n to the active ingredient, such carriers as are known in the art.
  • a flavor usually sucrose and acacia or tragacanth
  • pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addit n to the active ingredient, such carriers as are known in the art.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
  • Transurethral administration of the drug is preferred, although not essential.
  • the term "transurethral” is used to refer to delivery of the drug into the urethra, such that the drug contacts and passes through the wall of the urethra.
  • transurethral administration of a drug can be carried out in a number of different ways.
  • the drug can be introduced into the urethra from a flexible tube, squeeze bottle, pump or aerosol spray.
  • the drug may also be contained in coatings, pellets or suppositories, which are absorbed, melted or bioeroded in the urethra.
  • the drug is included in a coating on the exterior surface of a penile insert.
  • a preferred drug delivery device for administering a drug transurethrally is shown in Figure 1.
  • a transurethral drug delivery device is shown generally at 10.
  • the device comprises a transurethral insert 11 having an easily graspable segment 12 that has opposing symmetrically concave surfaces 13 and 14 adapted to be held by two fingers.
  • a drug is contained within the shaft 15, which is sized to fit within the urethra.
  • a longitudinal plunger, the top of which is seen at 16, is slidably insertable into the longitudinal bore contained within shaft 15.
  • shaft 15 is inserted into the urethra, and plunger tip 16 is pushed into segment 12.
  • the inserter 11 is then removed. Prior to use, and during storage, the device is capped with elongate cap
  • FIG. 1 is a preferred configuration, other inserter/container configurations can be used and any mechanism by which a predetermined quantity of drug can be introduced from the inserter at a predetermined depth in the urethra is suitable for use with this invention. Examples of other such devices are those described and illustrated in W091/16021, incorporated by reference above.
  • the devices can either be manufactured under sterile conditions, thereby eliminating the need for post- manufacturing sterilization, or they can be manufactured under non-sterile conditions and then subsequently sterilized by any suitable technique, e.g., radiation sterilization.
  • the devices can be manufactured by typical plastic forming and coating processes known in the art, including molding extrusion, heat forming, dip coating, and the like.
  • Transdermal drug administration involves the delivery of a pharmaceutical agent via percutaneous passage of the drug into the systemic circulation of the patient. See Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Hadgraft and Guy (eds.), Marcel Dekker, Inc., (1989); Controlled Drug Delivery:
  • transdermal patches may be used in the method described herein.
  • a simple adhesive patch can be used which is prepared from a backing material and an acrylate adhesive.
  • the adhesive layer is formulated so that a drug, and any carriers or enhancers to be used, are contained therein.
  • a hydrogel matrix patch can be used in which a drug, water and, typically, hydrophilic polymers, are used to form a hydrogel, which is then incorporated into a transdermal patch between the backing and the adhesive layer.
  • patch configurations can be used as well, including liquid reservoir patches, foam matrix patches, and the like. See, e.g., U.S. Patent Nos.
  • compositions and/or transdermal patches may be formulated with one or more preservatives or bacteriostatic agents, e.g., methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chloride, or the like.
  • the dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect a penile erection in the male over a reasonable time frame.
  • the dose will be determined by the strength of the particular nitric oxide-releasing agent employed, the type of delivery means employed, the route of administration, the condition and weight of the animal to be treated, the timing of administration, i.e., with respect to sexual intercourse, frequency of administration, and the length of time of administration.
  • the size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular composition or delivery means.
  • a suitable dose for example, is about 0.002 mg- 100 mg of nitric oxide.
  • the dose can be administered acutely or chronically, preferably acutely.
  • nitric oxide was recovered from this polymer on treatment with acid at the rate of 8 nmol of NO per milligram of solid.
  • This example illustrates the preparation of a polymer-bound nitric oxide/nucleophile adduct in which the N 2 0 2 " functional group is bound directly to an atom in the polymer backbone.
  • a slurry of 10.0 g of polyethyleneimine on silica gel (Aldrich) in 150 ml of acetonitrile was stirred for 3 days under a NO pressure of 5 at or 75-80 psig.
  • the resulting orange solid was filtered, washed with acetonitrile and then ether, and dried .in vacuo for 6 h.
  • This example illustrates the preparation of a polymer containing nitric oxide-releasing N 2 0 2 " groups that are attached to nucleophile residues pendant on the polymer backbone by the reaction of a primary amine with a derivatized polystyrene.
  • An aminostyrene polymer was prepared by warming 3.0 g of chloromethylated polystyrene (1% divinylbenzene; 1.09 mEq Cl per gram; 200-400 mesh; Polysciences, Inc., Warrington, PA) in 20 ml of n-propyl-1,3-propanediamine to 60 ⁇ C in an oil bath and swirling periodically for 5 days. The polymer was then filtered, washed repeatedly with water, then methanol and finally dichloromethane, and dried in vacuo for 24 h. Elemental analysis showed this material to be 2.21% nitrogen, indicating that approximately 80% of the chlorines had been replaced by propylpropanediamino groups.
  • nitric oxide can be recovered from the N 2 0 2 " group-containing polymers described above.
  • Example 4 This example illustrates the preparation of a polyethylene glycol-based NO-releasing polymer using two different methods of preparation. In both methods, the polymer-bound nitric oxide/nucleophile complex is formed by coprecipitation of a monomeric form of nitric- oxide/nucleophile compound with a polymer.
  • Example 5 This example illustrates the preparation of a polymer composed of a polyamine/nitric oxide complex, N- [4-[l-(3-aminopropyl)-2-hydroxy-2- nitrosohydrazino)butyl]-l,3-propanediamine, zwitterionic form (SPER/NO) ; and polyethylene glycol (PEG) formed by the coprecipitation of the polymer and nitric oxide/nucleophilic agent.
  • SPER/NO zwitterionic form
  • PEG polyethylene glycol
  • Example 6 This example describes the use of DEA/NO and SPER/NO to induce an erection in the anesthetized cat.
  • the anesthetized cat is a well-established model of erectile response for humans. Unlike other animal models that have been employed, the cat displays both structural and pharmacological similarities to erectile response in men. For example, with the exception of some primate species, the cat is the only animal model in which response to both NO donors and prostaglandins can be observed.
  • Figure 2 is a graph of corporal pressure (mm Hg) versus dose ( ⁇ g/200 ⁇ l) and depicts copropral pressure response to intracavemosal injection of NONOates in anesthetized cats. The results are expressed as mean ⁇ SEM of the intracavemosal pressure response in each animal.
  • the control is papaverine, 1.65 mg; phentolamine, 25 ⁇ g; and prostaglandin El, 0.5 ⁇ g, in a 200 ⁇ l injection volume.
  • Compound A is DEA/NO
  • compound B is prostaglandin El (PGEl)
  • compound C is SPER/NO
  • compound D is SNP.
  • Figure 3 is a graph of penile length change versus dose ( ⁇ g/200 ⁇ l) and depicts penile length change in response to intracavemosal injection of NONOates in anesthetized cats. Results are expressed as mean ⁇ SEM of the change in penile length from the length recorded after vehicle administration in each animal.
  • the control is papaverine, 1.65 mg; phentolamine, 25 ⁇ g; and prostaglandin El, 0.5 ⁇ g, in a 200 ⁇ l injection volume.
  • Compound A is DEA/NO
  • compound B is prostaglandin El (PGEl)
  • compound C is SPER/NO
  • compound D is SNP.
  • DEA/NO produced erections of comparable pressure, size and duration to that produced by combined treatment with papaverine, phentolamine and PGEl, which has been successfully used to treat men with organic dysfunction.

Abstract

A method of treatment for impotency is provided. The method involves the administration of nitric oxide by a nitric oxide-releasing agent capable of providing a penile erection-inducing amount of nitric oxide to the corpus cavernosum of the penis of an impotent male animal. Also provided is a nitric oxide delivery means for use in the method.

Description

U8E OF NITRIC OXIDE-RELEASING AGENTS TO TREAT IMPOTENCY
Technical Field of the Invention The present invention relates to a method of treating impotency in a male, and more particularly, to the use of certain nitric oxide-releasing agents to treat impotency. The present invention also relates to nitric oxide delivery means comprising nitric oxide- releasing agents for use in the method.
Background of the Invention It is estimated that in the United States alone, there are between 10 and 20 million men with moderate to severe forms of erectile dysfunction. An additional 10 million men exist for whom urinary tract dysfunction is also a significant problem.
Penile erection and detumescence involve a complex interaction of direct neuronal activation combined with the release of endothelial derived contractile and relaxant factors. A variety of neurotransmitter substances and vasoactive modulators have been described. Of these, nitric oxide appears to play a primary role in the development of an erection.
Cavernosal smooth muscle relaxation is one of the primary events in penile erection. Although it is believed to be initiated by the synthesis and release of NO from nonadrenergic-noncholinergic neurons of the corpus cavemosum (Kimura et al., Nippon Hinyokika Gakkai Zasshi 84(9): 1660-1664 (1993); Rajfer et al. , N. Engl. J. Med. 326(2): 90-94 (1992); Knispel et al., Urol. Res. 20(4): 253-257 (1992); Burnett et al., Science 257(5068): 401-403 (1992); and Mills et al. , Biol. Reprod. 46(3): 342-348 (1992)), studies undertaken to determine whether or not the serum levels of NO metabolites, i.e, nitrites and nitrates, increase in peripheral and cavernosal blood during penile erection in potent adult humans demonstrated that nitrite and nitrate levels do not change appreciably during and immediately following erection (Moriel et al., Urology 42(5): 551-553 (1993)). Physiological concentrations of oxygen in the corpus cavemosum tissue, however, are believed to modulate penile erection by regulating NO synthesis (Kim et al., J. Clin. Invest. 91(2): 437-442 (1993)). It has been further hypothesized that relaxation of the corpus cave osum, initiated in response to nitric oxide synthesis and release from nonadrenergic-noncholinergic neurons, could be amplified and maintained by NO production as a result of platelet trapping in the corpus cavemosum during the first phase of penile erection (Alberti et al., Minerva Urol. Nefrol. 45(2): 49-54 (1993)).
Currently available therapies for erectile dysfunction include needle injection of a vasodilator drugs directly into the penis; a vacuum constriction device (VCD) , which pulls blood into the penis and holds it there with a constriction ring; a surgical implant, which provides rigidity; oral medication, such as yohimbine, which appears to have beneficial effects in only a small proportion of patients; psychological therapy, for which few data exist on long term benefit; and vascular surgery, which is appropriate in only a very small number of patients. All six therapies have significant drawbacks. In fact, they are so limited in appeal that fewer than ten percent of men with erectile dysfunction have adopted any one of the therapies at all. In addition, each of these therapies suffers from exceedingly high rates of discontinuance for reasons that are not entirely related to the therapy, itself. There remains a need, therefore, for an effective method of treating impotency.
Nitric oxide has been utilized as a means of studying penile erection and penile dysfunction due to diabetes and venous leakage, for example. The potential usefulness of nitric oxide to treat impotence has been discussed by McGuffey (Am. Pharm. NS33(7): 20 (1993)).
Nitric oxide in its pure form, however, is a highly reactive gas having limited solubility in aqueous media (WHO Task Group on Environmental Health Criteria for Oxides of Nitrogen, Oxides of Nitrogen. Environmental Health Criteria 4 (World Health Organization: Geneva, 1977)). Nitric oxide, therefore, is difficult to introduce reliably into most biological systems without premature decomposition.
A number of compounds have been developed that are capable of delivering nitric oxide in a pharmacologically useful way. Such compounds include compounds that release nitric oxide upon being metabolized and compounds that release nitric oxide spontaneously in aqueous solution.
Compounds that release nitric oxide upon being metabolized include the widely used nitrovasodilators glyceryl trinitrate and sodium nitroprusside (SNP)
(Ignarro et al., J. Pharmacol. Exp. Ther.. 218. 739-749 (1981); Ignarro, Annu. Rev. Pharmacol. Toxicol.. 30. 535-560 (1990); Kruszyna et al., Toxicol. APDI. Pharmacol.. 91. 429-438 (1987); Wilcox et al., Chem. Res. Toxicol.. 2, 71-76 (1990)), which are relatively stable but release nitric oxide on activation. While this feature may be an advantage in some applications, it also can be a significant liability. For example, tolerance to glyceryl trinitrate can develop via the exhaustion of the relevant enzyme/cofactor system
(Ignarro et al., Annu. Rev. Pharmacol. Toxicol.. 25, 171-191 (1985); Kuhn et al., J. Cardiovasc. Pharmacol.. 14 (Suppl. 11), S47-S54 (1989)). Also, prolonged administration of nitroprusside results in the metabolic production of cyanide, which leads to toxicity (Smith et al., "A Potpourri of Biologically Reactive Intermediates" in Biological Reactive Intermediates IV. Molecular and Cellular Effects and Their Impact on Human Health (Witmer et al., eds.), Advances in Experimental Medicine and Biology Volume 283 (Plenum Press: New York, 1991), pp. 365-369) . S-Nitroso-N- acetylpenicillamine (SNAP) has been reported to release nitric oxide in solution and to be effective at inhibiting DNA synthesis (Garg et al., Biochem. and BioPhvs. Res. Co m.. HI, 474-479 (1990)).
SNP has been administered to primates for purposes of studying the physiology and pharmacology of erection (Hellstro et al., J. Urol. 151(60: 1723-1727 (1994)). Intracavernosal injection of SNP induced erections with dose-dependent increases in cavernosal pressure and penile length. The NO donor linsidomine chlorohydrate, otherwise known as 3-morpholinosydnonimine or SIN-1, was administered to 30 human patients with erectile dysfunction caused by venous leakage (Wegner et al. , Urology 42(4): 409-411 (1993)) and was less effective than prostaglandin El (PGEl) in treating the dysfunction in over two-thirds of the patients treated. SIN-1 was also found to be less effective than SNP in relaxing isolated rabbit corpus cavemosum (Holmquist et al., J. Urol. 150(4): 1310-1315 (1993)). More promising results with SIN-1 were obtained in a 63-patient study carried out by Stief et al. (J. Urol. 148(5): 1437-1440 (1992)). However, activation of SIN-l by oxygen produces both NO and superoxide ion, two species that can combine with one another to produce the potent oxidant, ONOO". The potential to produce this toxic by-product is believed to limit the utility of such sydnonimine drugs. Numerous nitric oxide-nucleophile complexes also have been described, e.g., by Drago, ACS Adv. Chem. Ser.. 3_6_, 143-149 (1962). See also Longhi and Drago, Inor . Chem.. Z, 85 (1963). Some of these complexes, known as NONOates, evolve nitric oxide on heating or hydrolysis (Maragos et al., J. Med. Chem.. 34. 3242-3247 (1991)) .
These compounds contain the anionic N202" group or derivatives thereof. Many of these compounds have proven especially promising pharmacologically because, unlike SNP and nitroglycerin, they release NO without first having to be activated. The only other series of drugs currently known to be capable of releasing NO purely spontaneously is the S-nitrosothiol series, compounds of structure R-S-N=0 (Stamler et al., Proc. Natl. Acad. Sci. U.S.A.. 8_£, 444-448 (1992)); however, the R-S-N=0→NO reaction can be kinetically complicated and difficult to control (Morley et al., J. Cardiovasc. Pharmacol.. 21. 670-676 (1993)), and extensive redox activation (McAninly et al., J. Chem. Soc, Chem. Comm.. 1758-1759 (1993)) and metabolism (Kowaluk et al., x__, Pharmacol. Exp. Ther.. 255. 1256-1264 (1990)) have been documented for these compounds. Moreover, the oxidation state of nitrogen in the S-nitrosothiols is +3, rather than the +2 of nitric oxide. While variation in the R group of the R-S-N=0 compounds provides a means of altering their chemical, and hence pharmacological, properties, the NONOate series is especially versatile in this respect. NONOates having reproducible half- lives ranging from 2 seconds to 20 hours have been prepared. They can be O-alkylated to provide either spontaneous NO-generators with half-lives of up to a week or more or prodrugs that cannot release NO at all until the oxygen substituent is removed etabolically. The NONOate function can be coordinated via the two oxygen atoms to metal centers; it can be attached to natural products, such as sper ine (a constituent of human semen) and peptides; and it can be bound in solid polymeric matrices to provide a point source of NO. A compound containing more than one nucleophile residue (such as, for example, the polya ine, sper ine) can be bound to more than one NONOate group, to thereby provide a single NONOate molecule with bi-or polyphasic NO release rates. By providing such a wide variety of NO release rates, physical forms, and potential strategies for targeting NO delivery to specific sites in the body, the NONOates constitute a most advantageous series of compounds on which to base NO donor drug development efforts.
Nitric oxide/nucleophile complexes (NONOates) that release nitric oxide in aqueous solution are disclosed in U.S. Patent Nos. 4,954,526, 5,039,705, 5,155,137,
5,185,376, 5,208,233, 5,212,204, 5,250,550, 5,366,977, and 5,389,675, as being useful cardiovascular agents (see also Maragos et al., J. Med. Chem.. 34. 3242-3247 (1991)). Despite the promise of the nitric oxide/nucleophile complexes that have been described thus far in the literature, their pharmacological application is limited by their tendency to distribute evenly throughout the medium. Such even distribution is a great advantage in many applications, but tends to compromise their selectivity of action. However, the nitric oxide/nucleophile complexes can be incorporated into polymers in order to overcome this limitation by enabling concentrated and localized release of NO at a given site in a controllable and predictable manner such that effective dosing can be realized. This imparts a tremendous advantage to the technology for the treatment of erectile dysfunction.
The present invention provides a method of treatment for impotency in a male animal that overcomes the above-described disadvantages of currently available treatment methods by employing NONOates as nitric oxide- releasing agents in the form of polymers, pharmaceutical compositions, and various delivery means comprising such compositions and polymers. Accordingly, the present invention also seeks to provide delivery means for use in the present inventive method. These and other objects and advantages of the present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.
Summary of the Invention
The present invention provides a method of treatment for impotency in a male animal, including a human. The method comprises the administration of a nitric oxide-releasing agent, which is capable of providing a penile erection-inducing amount of nitric oxide to the male animal and which includes a nitric oxide-releasing [N202] functional group. The nitric oxide-releasing agent can be a compound comprising a nitric oxide-releasing [N202] functional group, it can be a polymer to which is bound a nitric oxide-releasing
[N202] functional group, or it can be a delivery means, e.g., a transurethral applicator, penile implant, dermal patch or condom, comprising such a compound or polymer. In accordance with the method of the present invention, the nitric oxide-releasing agent provides NO to the penis of an impotent male animal in an amount sufficient to cause a penile erection.
In keeping with the invention, the delivery means can be coated with or made of a nitric oxide-releasing agent in the form of a polymer and enables the controllable and predictable release of NO to the penis in such a manner that effective therapeutic dosing of impotency is realized. The delivery means can be biodegradable. Delivery means comprising the nitric oxide-releasing agent are also provided. Brief Description of the Drawings Figure 1 illustrates an exploded view of one embodiment of a transurethral therapeutic device for delivery of the nitric oxide-releasing agent to the urethra.
Figure 2 is a graph of corporal pressure (mm Hg) versus dose (μg/200 μl) .
Figure 3 is a graph of penile length change versus dose (μg/200 μl) .
Detailed Description of the Invention The present invention provides a method for the treatment of impotency in a male animal, including a human. The method involves the administration to a male animal, in particular a human, of a nitric oxide- releasing agent. The nitric oxide-releasing agent can be a compound comprising a nitric oxide-releasing [N202] functional group or a polymer to which is bound a nitric oxide-releasing [N202] functional group or a delivery means, such as a transurethral applicator, a penile implant, a dermal patch or a condom, comprising such a compound or polymer. "Bound to a polymer" means that the [N202] functional group is associated with, part of, incorporated with or contained within the polymeric matrix either physically or chemically. Physical association or bonding of the N202 " functional group to the polymer may be achieved by coprecipitation of the polymer with a nitric oxide/nucleophile complex as well as by covalent bonding of the N202 " group to the polymer. Chemical bonding of the N202 " functional group to the polymer may be by, for example, covalent bonding of the nucleophile moiety of the nitric oxide/nucleophile adduct to the polymer such that the nucleophile residue to which the N202" group is attached forms part of the polymer itself, i.e., is in the polymer backbone or is attached to pendant groups on the polymer backbone. The manner in which the nitric oxide-releasing N202 " functional group is associated, part of, or incorporated with or contained within, i.e., "bound," to the polymer is inconsequential to the present invention and all means of association, incorporation and bonding are contemplated herein.
The delivery means can be coated with or made of a nitric oxide-releasing agent in the form of a polymer and enables the controllable and predictable release of NO to the penis in such a manner that effective therapeutic dosing of impotency is realized. "Nitric oxide delivery means" is meant to include the many forms in which the nitric oxide-releasing agent can be configured, such as a transurethral applicator, an implant, drug pump, catheter, self-adhering means, liposome, microparticle, solution, microsphere, bead, disk or other pharmaceutical composition as described more fully below. The delivery means can be biodegradable.
The nitric oxide-releasing agent provides NO to the penis of an impotent male animal in an amount sufficient to cause a penile erection. Determination of what amount is sufficient to induce a penile erection is as described below with respect to dosages. Whether or not a particular animal suffers from impotency is readily determined. Whether or not a particular animal is at risk for impotency can be assessed by those of skill in the art by taking into account known risk factors. Factors such as diabetes mellitus or venous leakage are likely to place a man at risk for impotency. The present invention also provides various nitric oxide delivery means for use in the present inventive method as described more fully below.
The nitric oxide-releasing [N202] functional group is X N(0)N0] or [N(0)NO-}-X, wherein X is an organic or inorganic moiety bonded to the - N(0)NO] or [N(O) on¬ functional group. The compound containing the [N202] functional group can be incorporated into or be part of a polymer. The [N202] group can be covalentiy bonded in the polymer by way of the moiety X. Incorporation of the N 02" functional group into a polymer enables localized release of NO to the penis. "Localized release" means into or adjacent to the corpus cavemosum. Localized release enhances the selectivity of action of the nitric oxide-releasing [N202] functional group. If [N202] functional groups attached to the polymer are localized, then the effect of their NO release will be concentrated in the tissues with which they are in contact. If the polymer is soluble, selectivity of action can still be arranged, for example, by attachment to or derivatization of an antibody specific to the target tissue. Similarly, attachment of [N20 ] functional groups to small peptides that mimic the recognition sequences of ligands for important receptors provides localized, concentrated NO release, as would attachment to oligonucleotides capable of site-specific interactions with target sequences in a nucleic acid.
Additionally, incorporation of the [N202] functional group into a polymer can reduce the propensity of the nitric oxide/nucleophile adduct for the relatively rapid release of NO. This prolongs the release of NO by the [N202J functional group, and allows for efficient dosing to achieve a penile erection and, possibly, concomitant reduction in the frequency of dosing.
While not being bound to any particular theory, it is believed that longevity of nitric oxide release in the polymer-bound nitric oxide/nucleophile adduct compositions of the present invention is to be attributed both to the physical structure of the composition and to electrostatic effects. Thus, it is believed that if the polymer is an insoluble solid, N202 " groups near the surface of the particle should be available for rapid release while those that are more deeply imbedded are sterically shielded, requiring more time and/or energy for the nitric oxide to work its way into the medium. Unexpectedly, it has been found that increasing positive charge in the vicinity of an N202 ~ functional group also tends to increase the halflife of nitric oxide generation. The mechanism of this rate retardation may be attributable simply to repulsive electrostatic interactions, i.e., increasing the number of H+-repelling positive charges in the vicinity of the N202 " groups inhibits attack of positively charged H+ ions on the N202" functional group and slows the rate of its H+- catalyzed decomposition. For example, by attaching amino groups to the polymeric support that are capable of forming the nitric oxide-releasing N202" functional group on reaction with nitric oxide, partially converted structures can be produced on less- than-exhaustive treatment with nitric oxide that after exposure to water contain a large number of positively charged ammonium centers surrounding the N202 ~ group that electrostatically inhibit the approach of H+ ions capable of initiating nitric oxide loss from the nitric oxide releasing N202" functional group.
The nitric oxide-releasing [N 02] functional groups that are bound to the polymer generally are capable of releasing NO in an aqueous environment spontaneously upon contacting an aqueous environment, i.e., they do not require activation through a redox reaction or electron transfer, such as is required for glyceryl trinitrate and SNP. Some of the nitric oxide/nucleophile complexes useful in the context of the present invention do require activation by particular means, but only as necessary to free the nitric oxide- releasing X-£-N(0)NO]~ group in the vicinity of the penis or corpus cavemosum. As an example, covalent attachment of a protecting group to the anionic [N(0)N0]~ function provides a means of postponing NO release until the molecule reaches the penis, where cells/tissues are capable of metabolically removing the protecting group. While the polymer-bound, nitric oxide-releasing compositions of the present invention are capable of releasing NO in an aqueous solution, such a polymer preferably releases NO under physiological conditions.
The nitric oxide-releasing [N202] functional group is preferably a nitric oxide/nucleophile adduct, i.e., a complex of NO and a nucleophile, most preferably a nitric oxide/nucleophile complex which contains the anionic moiety X N(0)N0]", wherein X is any suitable nucleophile residue. The nucleophile residue is preferably that of a primary amine (e.g., X = (CH3)2CHNH, as in (CH3)2CHNH[N(0)NO]Na) , a secondary amine (e.g., X - (CH3CH2)2N, as in (CH3CH2)2N[N(0)NO]Na) , a polyamine (e.g., X s sper ine, as in the zwitterion H2N(CH2)3NH2 +(CH2)4N[N(0)NO]~(CH2)3NH2, X - (ethylamino)ethylamine, as in the zwitterion CH3CH2N[N(0)NO]"CH2CH2NH3 +, or X - 3-(n-propylamino)propylamine, as in the zwitterion CH3CH2CH2N[N(0)NO]"CH2CH2CH2NH3 +) , or oxide (i.e., X = 0", as in NaO[N(0)NO]Na) , or a derivative thereof. Such nitric oxide/nucleophile complexes are stable solids and are capable of delivering NO in a biologically usable form at a predictable rate. The nucleophile residue is preferably not an entity such as that of sulfite (e.g., X = S03~, as in NH403S[N(0)NO]NH4) even though the complex is a stable compound, since it is capable of releasing NO in an aqueous environment only under harsh, nonphysiological conditions.
Other suitable nitric oxide/nucleophile complexes include those having the following formulas:
Figure imgf000014_0001
wherein J is an organic or inorganic moiety, including, for example, a moiety which is not linked to the nitrogen of the [N202] group through a carbon atom, M*x is a pharmaceutically acceptable cation, where x is the valence of the cation, a is 1 or 2, and b and c are the smallest integers that result in a neutral compound, preferably such that the compound is not a salt of alanosine or dopastin, as described in U.S. Patent No. 5,212,204, incorporated herein by reference;
R1-NH+-(CH2)χ-N-[(CH2)yN]d-[(CH2)z-N]b-R3 (II)
N202"
wherein b and d are the same or different and may be zero or one, R1; R2, R3, R4, and R5 are the same or different and may be hydrogen, C3_8 cycloalkyl, C1-12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, and x, y, and z are the same or different and are integers from 2 to 12, as described in U.S. Patent No. 5,155,137, incorporated herein by reference;
Figure imgf000015_0001
wherein B is or —N N— 202 ~ ,
Figure imgf000015_0002
R6 and R7 are the same or different and may be hydrogen, 3-8 cycloalkyl, C1_12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-trichloro- t-butoxycarbonyl, f is an integer from 0 to 12, with the proviso that when B is the substituted piperazine moiety — N N-N202 "
then f is an integer from 2 to 12, as described in U.S, Patent 5,250,550 incorporated herein by reference;
Figure imgf000016_0001
wherein R8 is hydrogen, C3_8 cycloalkyl, C1-12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-tri-chloro-t-butoxycarbonyl, R9 is hydrogen or a C1-C12 straight or branched chain alkyl, and g is 2 to 6, as described in U.S. Patent No. 5,250,550, incorporated herein by reference;
Figure imgf000016_0002
wherein R-*^ and R2 are independently selected from the group consisting of a straight chain or branched chain l ~ C 12 a^kyl group and a benzyl group, preferably such that no branch occurs on the alpha carbon atom, or else Rχ and R2, together with the nitrogen atom to which they are bonded, form a heterocyclic group, preferably a pyrrolidino, piperidino, piperazino or morpholino group, M+x is a pharmaceutically acceptable cation, and x is the valence of the cation, as described in U.S. Patent Nos. 5,039,705 and 5,208,233 and U.S. patent application Serial No. 08/017,270, filed February 12, 1993, and incorporated herein by reference; K [ (M) x χ '( L) y (R1R2N-N202 ) z ] (VI )
wherein M is a pharmaceutically acceptable metal, or, where x is at least two, a mixture of two different pharmaceutically acceptable metals, L is a ligand different from (R1R2N-N202) and is bound to at least one metal, R1 and R2 are each organic moieties and may be the same or different (preferably where M is copper, x is one, L is methanol, and y is one, that at least one of R1 or R2 is not ethyl) , x is an integer of from 1 to 10, x' is the formal oxidation state of the metal M, and is an integer of from 1 to 6, y is an integer of from 1 to 18, and where y is at least 2, the ligands L may be the same or different, z is an integer of from 1 to 20, and K is a pharmaceutically acceptable counterion to render the compound neutral to the extent necessary, as described in U.S. Patent 5,389,675 and incorporated herein by reference; [R-N(H)N(NO)0-]yX (VII)
wherein R is C _8 lower alkyl, phenyl, benzyl, or C3_8 cycoloalkyl, any of which R groups may be substituted by one to three substituents, which are the same or different, selected from the group consisting of halo, hydroxy, C^g alkoxy, -NH2, -C(0)NH2, -CH(O) , -C(0)OH, and -N02, X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from the group consisting of C1_8 lower alkyl, -C(0)CH3, and -C(0)NH2, and y is one to three, consistent with the valence of X, as described in U.S. Patent No. 4,954,526 and incorporated herein by reference; and
Figure imgf000017_0001
wherein Rχ and R2 are independently chosen from Cj ., straight chain alkyl, C1_12 alkoxy or acyloxy substituted straight chain alkyl, C2_12 hydroxy or halo substituted straight chain alkyl, C3_12 branched chain alkyl, C3_12 hydroxy, halo, alkoxy, or acyloxy substituted branched chain alkyl, C3_12 straight chain olefinic and C3_12 branched chain olefinic which are unsubstituted or substituted with hydroxy, alkoxy, acyloxy, halo or benzyl, or ϊ\1 and R2, together with the nitrogen atom to which they are bonded, form a heterocyclic group, preferably a pyrrolidino, piperidino, piperazino or morpholino group, and R3 is a group selected from C1-1 straight chain and C3_12 branched chain alkyl which are unsubstituted or substituted by hydroxy, halo, acyloxy or alkoxy, C2_12 straight chain or C3_12 branched chain olefinic which are unsubstituted or substituted by halo, alkoxy, acyloxy or hydroxy, C1_12 unsubstituted or substituted acyl, sulfonyl and carboxamido; or R3 is a group of the formula -(CH2)n-ON=N(0)NR1R2, wherein n is an integer of 2-8, and Rx and R2 are as defined above; preferably Rlf R2 and R3 do not contain a halo or a hydroxy substituent a to a heteroatom, as described in U.S. Patent 5,366,997.
Any of a wide variety of polymers can be used in the context of the present invention. It is only necessary that the polymer selected be biologically acceptable. Illustrative of polymers suitable for use in the present invention are polyolefins, such as polystyrene, polypropylene, polyethylene, polytetrafluorethylene, polyvinylidene difluoride, polyvinylchloride, polyethyleneimine, and derivatives thereof; polyethers, such as polyethyleneglycol; polyesters, such as poly(lactide/glycolide) ; polyamides, such as nylon; polyurethanes; starburst dendimers biopolymers, such as peptides or proteins (e.g., antibodies), nucleic acids (e.g., oligonucleotides), and the like. The physical and structural characteristics of the polymers suitable for use in the present invention are not narrowly critical, but rather will depend on the route and frequency of administration. The polymer can be biodegradable.
The nitric oxide-releasing agents can be administered in a wide variety of forms of delivery means. Any delivery means should adequately protect the integrity of the NO prior to its release and should control the release of the NO at such a rate, in such an amount, and in such a location as to serve as an effective means of treating the impotency. For example, delivery means for local administration or administration for localized release include, but are not limited to, a penile implant, a drug pump, a drug- delivery catheter (pressure-driven, iontophoretic or transurethral) , a self-adhering means, a liposoroe, a microparticle, a microsphere, a bead, a condom, a dermal patch, a disk or other device. The advantages of local administration or localized release include the ability to attain effective concentrations of NO at the target site more quickly, the use of a smaller dose, and the realization of fewer toxic side effects than could occur on systemic administration and release. Delivery means for systemic administration for localized release include, but are not limited to, solutions, suspensions, emulsions, capsules, sachets, tablets, dermal (topical) patches, lozenges, aerosols, liposomes, microparticles, microspheres, beads, prodrugs, tissue-specific antibodies, small peptides that mimic ligand recognition sequences, and sequence-specific oligonucleotides as described above. The polymer, itself, may be structurally sufficient to serve as a form of delivery means. Alternatively, the polymer can be incorporated into or coated onto other matrices, substrates or the like, or can be microencapsulated or the like. The nitric oxide-releasing [N202] functional groups, including the compounds described above, can be bound to a polymeric support in a number of different ways. For example, the compounds described above can be bound to the polymer by coprecipitation of such compounds with the polymer. Coprecipitation can involve, for example, solubilizing both the polymer and the nitric oxide/nucleophile compound and evaporating the solvent. Monomers containing the [N 02] group also can be dissolved in molten polymer, which, upon solidification when the temperature is lowered, contains a rather uniform distribution of [N202] groups within the matrix.
The [N 0 ] functional group can be attached to an atom in the backbone of the polymer, or it can be attached to a group pendant to the polymer backbone, or it can simply be entrapped in the polymeric matrix. Where the [N 02] functional group is in the polymer backbone, the polymer includes, in its backbone, sites that are capable of reacting with NO to bind the NO for future release. For example, where the polymer is polyethyleneimine, the polymer includes nucleophilic nitrogen atoms, which react with NO to form the [N202] functional group at the nitrogen in the backbone. Where the [N202] functional group is a group pendant to the polymer backbone, the polymer can contain, or be derivatized with, a suitable nucleophilic residue capable of reacting with NO to form the [N202] functionality. Reaction of the polymer that contains a suitable nucleophilic residue, or of the suitably derivatized polymer, with NO thus provides a polymer- bound nitric oxide-releasing [N202] functional group.
One skilled in the art will appreciate that suitable methods of administering the nitric oxide- releasing agents of the present invention to a male animal, including a human male, are available, and, although more than one route can be used to administer a particular compound or polymer, a particular route can provide a more immediate and more effective result than another route. Pharmaceutically acceptable carriers are also well-known to those who are skilled in the art. The choice of carrier for a pharmaceutical composition will be determined in part by the particular composition, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions for use in the present invention. Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the polymer-bound composition dissolved in diluents, such as water or saline, (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solids or granules, (c) suspensions in an appropriate liquid, and (d) suitable emulsions. Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addit n to the active ingredient, such carriers as are known in the art.
Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
Transurethral administration of the drug is preferred, although not essential. The term "transurethral" is used to refer to delivery of the drug into the urethra, such that the drug contacts and passes through the wall of the urethra. As explained in co- pending U.S. patent application Serial No. 07/514,397, entitled "Treatment of Erectile Dysfunction" (published internationally as WO91/16021), the disclosure of which is incorporated by reference herein, transurethral administration of a drug can be carried out in a number of different ways. For example, the drug can be introduced into the urethra from a flexible tube, squeeze bottle, pump or aerosol spray. The drug may also be contained in coatings, pellets or suppositories, which are absorbed, melted or bioeroded in the urethra. In certain embodiments, the drug is included in a coating on the exterior surface of a penile insert. A preferred drug delivery device for administering a drug transurethrally is shown in Figure 1. In Figure 1, a transurethral drug delivery device is shown generally at 10. The device comprises a transurethral insert 11 having an easily graspable segment 12 that has opposing symmetrically concave surfaces 13 and 14 adapted to be held by two fingers. A drug is contained within the shaft 15, which is sized to fit within the urethra. A longitudinal plunger, the top of which is seen at 16, is slidably insertable into the longitudinal bore contained within shaft 15. To extrude a drug into the urethra, shaft 15 is inserted into the urethra, and plunger tip 16 is pushed into segment 12. The inserter 11 is then removed. Prior to use, and during storage, the device is capped with elongate cap
17, which fits snugly over flange 18 at the proximal end of shaft 15. The cap 17 is provided with a series of parallel ridges 19 to facilitate gripping of the cap and removal from inserter 11. Although the configuration shown in Figure 1 is a preferred configuration, other inserter/container configurations can be used and any mechanism by which a predetermined quantity of drug can be introduced from the inserter at a predetermined depth in the urethra is suitable for use with this invention. Examples of other such devices are those described and illustrated in W091/16021, incorporated by reference above. The devices can either be manufactured under sterile conditions, thereby eliminating the need for post- manufacturing sterilization, or they can be manufactured under non-sterile conditions and then subsequently sterilized by any suitable technique, e.g., radiation sterilization. The devices can be manufactured by typical plastic forming and coating processes known in the art, including molding extrusion, heat forming, dip coating, and the like.
The drug also may be administered topically, transdermally or by any other available and effective means. Transdermal drug administration, as is well known to those skilled in the art, involves the delivery of a pharmaceutical agent via percutaneous passage of the drug into the systemic circulation of the patient. See Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Hadgraft and Guy (eds.), Marcel Dekker, Inc., (1989); Controlled Drug Delivery:
Fundamentals and Applications, Robinson and Lee (eds.), Marcel Dekker Inc., (1987); and Transdermal Delivery of Drugs, Vols. 1-3, Kydonieus and Berner (eds.), CRC Press (1987) .
A variety of types of transdermal patches may be used in the method described herein. For example, a simple adhesive patch can be used which is prepared from a backing material and an acrylate adhesive. The adhesive layer is formulated so that a drug, and any carriers or enhancers to be used, are contained therein. Alternatively, a hydrogel matrix patch can be used in which a drug, water and, typically, hydrophilic polymers, are used to form a hydrogel, which is then incorporated into a transdermal patch between the backing and the adhesive layer. As will be appreciated by those skilled in the art, a number of other types of patch configurations can be used as well, including liquid reservoir patches, foam matrix patches, and the like. See, e.g., U.S. Patent Nos. 3,598,122, 4,649,075 and 5,120,544, the disclosures of which are incorporated by reference herein. Other components may be incorporated into such transdermal patches as well. For example, compositions and/or transdermal patches may be formulated with one or more preservatives or bacteriostatic agents, e.g., methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chloride, or the like.
The dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect a penile erection in the male over a reasonable time frame. The dose will be determined by the strength of the particular nitric oxide-releasing agent employed, the type of delivery means employed, the route of administration, the condition and weight of the animal to be treated, the timing of administration, i.e., with respect to sexual intercourse, frequency of administration, and the length of time of administration. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular composition or delivery means. A suitable dose, for example, is about 0.002 mg- 100 mg of nitric oxide. The dose can be administered acutely or chronically, preferably acutely.
The following examples further illustrate the present invention, but do not limit the scope thereof.
Exam le l This example illustrates the preparation of a polymer-bound nitric oxide/nucleophile complex by coprecipitation of a monomeric form thereof with a polymer.
One gram of polymer [poly(lactide/glycolide, 50:50) from MediSorb] was dissolved in 2 ml of tetrahydrofuran. To the solution was added 300 mg of DETA/NO, [H2N(CH2)2]2N-N 02H, zwitterionic form, and the mixture was stirred under an argon stream to remove solvent slowly until the mixture became too viscous to stir. The mixture was then placed in a vacuum oven (ca. 1 mm) at 30°C for 5 hours to remove the residual solvent. The mixture was finally pressed on a carver press at 20,000 lbs. at 140βF for 5 minutes. A 1" x 1" film, 44 mils thick, was thus prepared. Using a chemiluminescence procedure as described in Maragos et al., J. Med. Chem.. 34. 3242-3247 (1991) , nitric oxide was recovered from this polymer on treatment with acid at the rate of 8 nmol of NO per milligram of solid.
Example 2
This example illustrates the preparation of a polymer-bound nitric oxide/nucleophile adduct in which the N202" functional group is bound directly to an atom in the polymer backbone. A slurry of 10.0 g of polyethyleneimine on silica gel (Aldrich) in 150 ml of acetonitrile was stirred for 3 days under a NO pressure of 5 at or 75-80 psig. The resulting orange solid was filtered, washed with acetonitrile and then ether, and dried .in vacuo for 6 h. Using the chemiluminescence procedure identified in Example 1, it was determined that NO was recovered from this polymer on treatment with acid at the rate of 3 nmol/mg.
Control experiments with polymer that had not been exposed to NO produced no chemiluminescence signal.
Example 3
This example illustrates the preparation of a polymer containing nitric oxide-releasing N202" groups that are attached to nucleophile residues pendant on the polymer backbone by the reaction of a primary amine with a derivatized polystyrene.
An aminostyrene polymer was prepared by warming 3.0 g of chloromethylated polystyrene (1% divinylbenzene; 1.09 mEq Cl per gram; 200-400 mesh; Polysciences, Inc., Warrington, PA) in 20 ml of n-propyl-1,3-propanediamine to 60βC in an oil bath and swirling periodically for 5 days. The polymer was then filtered, washed repeatedly with water, then methanol and finally dichloromethane, and dried in vacuo for 24 h. Elemental analysis showed this material to be 2.21% nitrogen, indicating that approximately 80% of the chlorines had been replaced by propylpropanediamino groups.
A slurry of 1.0 g of the aminopolystyrene polymer in 50 ml of acetonitrile was placed under 5 atm of nitric oxide in a Parr apparatus and shaken intermittently for 3 days. The product was filtered and dried i_\ vacuo to yield 0.84 g of cream colored polymer. The elemental analysis (C: 87.32; H: 8.00; N: 2.45) revealed that approximately one-third of the amino side chains became attached to N202 " groups under these conditions.
Using the chemiluminescence procedure of Maragos et al. (vide supra) , it was demonstrated that nitric oxide can be recovered from the N202 " group-containing polymers described above.
Example 4 This example illustrates the preparation of a polyethylene glycol-based NO-releasing polymer using two different methods of preparation. In both methods, the polymer-bound nitric oxide/nucleophile complex is formed by coprecipitation of a monomeric form of nitric- oxide/nucleophile compound with a polymer.
In one method, 20 mg of 1, l-diethyl-2-hydroxy-2- nitrosohydrazine sodium salt (DEA/NO) and 2.5 g of polyethylene glycol-1450 (Union Carbide) were dissolved in 25 ml of methanol. The homogeneous solution was placed on a rotary evaporator at 40°C and the solvent was removed under vacuum to give a uniform solid solution. The sample was stored in a clear glass vial, under ordinary laboratory lighting, at ambient temperature and atmosphere. The stability of the formulation was followed over a period of seven days. The measurements were carried out by monitoring the absorbance of the polymer at the 250 nm peak in the electronic spectrum. No changes in the absorbance were observed in this time period. In a second method, 2.5 g of polyethylene glycol-
1450 was heated to 46°C until completely melted. To the liquid polyethylene glycol was added 36 mg (0.232 mmol) of DEA/NO and the container was placed on a vortex mixer. A homogeneous solution was attained that gradually solidified upon cooling to ambient temperature. The stability of the solution was monitored as described above. No change in the absorbance for the 250 nm chromophore was observed at seven weeks of storage. Example 5 This example illustrates the preparation of a polymer composed of a polyamine/nitric oxide complex, N- [4-[l-(3-aminopropyl)-2-hydroxy-2- nitrosohydrazino)butyl]-l,3-propanediamine, zwitterionic form (SPER/NO) ; and polyethylene glycol (PEG) formed by the coprecipitation of the polymer and nitric oxide/nucleophilic agent.
A 1.2% (w/w) solution of KOH in polyethylene glycol-1450 (Union Carbide) was prepared in aqueous medium, and evaporated to dryness under vacuum (PEG- KOH) . To 1.144 g of molten PEG-KOH was added 11.65 mg (0.042 mmol) of SPER/NO and the resulting mixture was blended to a uniform mass. No decrease was observed in the absorbance after five weeks of storage at room temperature in a clear glass vial.
Example 6 This example describes the use of DEA/NO and SPER/NO to induce an erection in the anesthetized cat. The anesthetized cat is a well-established model of erectile response for humans. Unlike other animal models that have been employed, the cat displays both structural and pharmacological similarities to erectile response in men. For example, with the exception of some primate species, the cat is the only animal model in which response to both NO donors and prostaglandins can be observed.
Anesthetized adult male cats were given intracavemosal injections of various vasoactive agents, either alone or in combination, to determine their efficacy on intracorporal pressure and penile length change (Wang et al., J. Urol. 151: 234-237 (1994)). Each administration of a test compound was followed by the administration of a control compound so that the response of the test compound could be compared to the control compound. DEA/NO and SPER/NO were dissolved in 10 M NaOH and papaverine (1.65 mg) , phentolamine (25 μg) , prostaglandin El (PGEl) (0.5 μg) , 200 μl vehicle, and 10 mM NaOH solution served as controls. Compounds were handled identically and administered over the dosage range of 3, 10 and 30 μg/200 μl injection.
The results of the testing are shown in Figures 2 and 3. Figure 2 is a graph of corporal pressure (mm Hg) versus dose (μg/200 μl) and depicts copropral pressure response to intracavemosal injection of NONOates in anesthetized cats. The results are expressed as mean ± SEM of the intracavemosal pressure response in each animal. The control is papaverine, 1.65 mg; phentolamine, 25 μg; and prostaglandin El, 0.5 μg, in a 200 μl injection volume. Compound A is DEA/NO, compound B is prostaglandin El (PGEl) , compound C is SPER/NO, and compound D is SNP. Figure 3 is a graph of penile length change versus dose (μg/200 μl) and depicts penile length change in response to intracavemosal injection of NONOates in anesthetized cats. Results are expressed as mean ± SEM of the change in penile length from the length recorded after vehicle administration in each animal. The control is papaverine, 1.65 mg; phentolamine, 25 μg; and prostaglandin El, 0.5 μg, in a 200 μl injection volume. Compound A is DEA/NO, compound B is prostaglandin El (PGEl) , compound C is SPER/NO, and compound D is SNP. The results show that increases in corporal pressure were obtained with DEA/NO (compound A) , SNP (compound D) and PGEl (compound B) . An increase in penile length was obtained with SPER/NO (compound C) at a higher dose. The effect of SPER/NO appears to be related to its relative potency as well as its longer rate of release of NO.
The results show the usefulness of NONOates as NO donors for the treatment of erectile dysfunction.
DEA/NO produced erections of comparable pressure, size and duration to that produced by combined treatment with papaverine, phentolamine and PGEl, which has been successfully used to treat men with organic dysfunction. The results suggest that DEA/NO and SPER/NO can be used together in a synergistic manner to produce erections of rapid onset and sufficient rigidity and duration.
All publications, patents, and patent applications cited herein are hereby incorporated by reference to the same extent as if each individual document were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
While this invention has been described with emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that the preferred embodiments may be varied. It is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A method for the treatment of impotency in a male animal, which method comprises the administration to said male of a nitric oxide-releasing agent, said agent being selected from the group consisting of a compound, a polymer, a nitric oxide delivery means comprising said compound, and a nitric oxide delivery means comprising said polymer, wherein said compound and said polymer comprise at least one nitric oxide- releasing [N 02] functional group selected from the group consisting of X-f-N(0)N0] and [N(0)N0-3-X, wherein X is a moiety bonded to said -£N(0)NO] or [N(0)NO-}-, and wherein the -£N(0)NO] or [N(0)NO-3- group is bonded in said polymer through said moiety X, said agent providing a penile erection-inducing amount of nitric oxide to said male animal.
2. The method of claim 1, wherein said nitric oxide-releasing [N 02] functional group is from a compound of the formula selected from the group consisting of I, II, III, IV, V, VI, VII and VIII as follows:
Figure imgf000031_0001
wherein J is an organic or inorganic moiety, M x is a pharmaceutically acceptable cation, where x is the valence of the cation, a is 1 or 2, and b and c are the smallest integers that result in a neutral compound;
R1-NH+-(CH2)χ-N-[(CH2) N]d-[(CH2)Z-N]b-R3 (II)
N202 "
wherein b and d are the same or different and are zero or one, Rχ, R2, R3, R4, and R5 are the same or different and are hydrogen, C3_8 cycloalkyl, C1_12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2, 2-trichloro-t-butoxycarbonyl, and x, y, and z are the same or different and are integers from 2 to 12;
Figure imgf000032_0001
wherein B is or — N-N202 "
Figure imgf000032_0002
R6 and R7 are the same or different and are hydrogen,
C3_8 cycloalkyl, C1_12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-trichloro- t-butoxycarbonyl, f is an integer from 0 to 12, with the proviso that when B is the substituted piperazine moiety
—N N-N202 "
then f is an integer from 2 to 12,
Figure imgf000032_0003
wherein R8 is hydrogen, C3_8 cycloalkyl, C1_12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-tri-chloro-t-butoxycarbonyl, R9 is hydrogen or a C1-C12 straight or branched chain alkyl, and g is 2 to 6;
Figure imgf000033_0001
wherein Rx and R2 are independently selected from the group consisting of a C1-C12 straight or branched chain alkyl and benzyl, M+x is a pharmaceutically acceptable cation, and x is the valence of the cation;
K[(M) xX'(L)y(RAlRr Ω2*Nrl--N202)z] (VI)
wherein M is a pharmaceutically acceptable metal, or where x is at least two, a mixture of two different pharmaceutically acceptable metals, L is a ligand different from (R1R2N-N202) and is bound to at least one metal, R1 and R2 are each organic moieties and are the same or different, x is an integer of from 1 to 10, x' is the formal oxidation state of the metal M, and is an integer of from l to 6, y is an integer of from l to 18, with the proviso that y is at least 2, the ligands L are the same or different, z is an integer from 1 to 20, and K is a pharmaceutically acceptable counterion to render the compound neutral to the extent necessary;
[R-N(H)N(N0)0-]yX (VII)
wherein R is C2_8 lower alkyl, phenyl, benzyl, or C3_8 cycloalkyl, any of which R groups can be substituted by one to three substituents, which are the same or different, and are selected from the group consisting of halo, hydroxy, C1_8 alkoxy, -NH2, -C(0)NH2, -CH(O), -C(0)OH, and -N02, X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from the group consisting of C-^g lower alkyl, -C(0)CH3, and -C(0)NH2, and y is an integer from 1 to 3, consistent with the valence of X; and
R1R2N-N-*0 (VIII) II
N-OR3
wherein Rλ and R2 are independently chosen from λ_12 straight chain alkyl, C1_12 alkoxy or acyloxy substituted straight chain alkyl, C2_12 hydroxy or halo substituted straight chain alkyl, C3_12 branched chain alkyl, C3_12 hydroxy, halo, alkoxy, or acyloxy substituted branched chain alkyl, a C3_12 straight or branched chain olefinic unsubstituted or substituted with hydroxy, alkoxy, acyloxy, halo or benzyl, or -^ and R2 together with the nitrogen atom to which they are bonded form a heterocyclic group, and R3 is a group selected from C1_12 straight chain and C3_12 branched chain alkyl which are unsubstituted or substituted by hydroxy, halo, acyloxy or alkoxy, C2_1 straight chain or C3_12 branched chain olefinic which are unsubstituted or substituted by halo, alkoxy, acyloxy or hydroxy, C1_12 unsubstituted or substituted acyl, sulfonyl and carboxa ido; or R3 is a group of the formula -(CH2)n-ON*=N(0)NR1R2, wherein n is an integer of 2-8, and R: and R2 are as defined above.
3. The method of claim 2, wherein said nitric oxide-releasing [N202] functional group is from a compound of formula III, and B is the substituted piperazine moiety
—N N- 202 "
4. The method of claim 2, wherein said nitric oxide-releasing [N202] functional group is from a compound of formula V, and Rχ and R2 are selected so that Rj and R2, together with the nitrogen atom to which they are bonded, form a heterocyclic group.
5. The method of claim 4, wherein the heterocyclic group is selected from the group consisting of pyrrolidino, piperidino, piperazino and morpholino.
6. The method of claim 2, wherein said nitric oxide-releasing [N202] functional group is from a compound of formula VIII, and the heterocyclic group is selected from the group consisting of pyrrolidino, piperidino, piperazino, and morpholino.
7. The method of claim 1, wherein the moiety X of said functional group is part of the polymeric backbone.
8. The method of claim 1, wherein the moiety X of said functional group is part of a group pendant to the polymeric backbone.
9. The method of claim 1, wherein said polymer is selected from the group consisting of polyolefins, polyethers, polyesters, polyamides, polyurethanes, and biopolymers.
10. The method of claim 9, wherein the biopolymer is selected from the group consisting of a peptide, a protein, and a nucleic acid.
11. The method of claim 1, wherein said nitric oxide delivery means is selected from the group consisting of a transurethral applicator, a penile implant, a drug pump, a catheter, a self-adhering means, a liposome, a microparticle, a microsphere, a bead, a disk, a dermal patch and a condom.
12. A method for the treatment of impotency in a male animal, which method comprises the administration to said male animal of a nitric oxide-releasing agent, said agent being selected from the group consisting of a coprecipitation product of a polymer selected from the group consisting of a polyolefin, a polyether, a polyester, a polyamide, a polyurethane, and a biopolymer, and a compound comprising a nitric oxide- releasing [N202] functional group.
13. The method of claim 12, wherein said compound comprising a nitric oxide-releasing [N202] functional group is a compound of the formula selected from the group consisting of I, II, III, IV, V, VI, VII and VIII as follows:
Figure imgf000036_0001
wherein J is an organic or inorganic moiety, M x is a pharmaceutically acceptable cation, where x is the valence of the cation, a is 1 or 2, and b and c are the smallest integers that result in a neutral compound;
R1-NH+-(CH2)χ-N-[(CH2) N]d-[(CH2)Z-N]b-R3 (ID
N202 ' Re
wherein b and d are the same or different and are zero or one, R:, R2, R3, R4, and R5 are the same or different and are hydrogen, C3_8 cycloalkyl, C1_12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, and x, y, and z are the same or different and are integers from 2 to 12;
Figure imgf000037_0001
wherein B is or -N N-N202 "
Figure imgf000037_0002
R6 and R7 are the same or different and are hydrogen,
C3_8 cycloalkyl, Cλ.12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2, 2 , 2-trichloro- t-butoxycarbonyl, f is an integer from 0 to 12, with the proviso that when B is the substituted piperazine moiety
—N N-N202 "
then f is an integer from 2 to 12 ;
(εr (CH2)g-
Figure imgf000037_0003
wherein R8 is hydrogen, C3_8 cycloalkyl, C1_12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2, 2 ,2-tri-chloro-t-butoxycarbonyl, R9 is hydrogen or a C 1~C 12 straight or branched chain alkyl, and g is 2 to 6;
Figure imgf000037_0004
wherein Rx and R2 are independently selected from the group consisting of a C1-C12 straight or branched chain alkyl and benzyl, M+x is a pharmaceutically acceptable cation, and x is the valence of the cation;
K[(M)x χ(L)y(R1R2N-N202)z] (VI)
wherein M is a pharmaceutically acceptable metal, or where x is at least two, a mixture of two different pharmaceutically acceptable metals, L is a ligand different from (R1R2N-N202) and is bound to at least one metal, R1 and R2 are each organic moieties and are the same or different, x is an integer of from 1 to 10, x' is the formal oxidation state of the metal M, and is an integer of from 1 to 6, y is an integer of from 1 to 18, with the proviso that y is at least 2, the ligands L are the same or different, z is an integer from 1 to 20, and K is a pharmaceutically acceptable counterion to render the compound neutral to the extent necessary;
[R-N(H)N(N0)0-]yX (VII)
wherein R is C2_8 lower alkyl, phenyl, benzyl, or C3_8 cycloalkyl, any of which R groups can be substituted by one to three substituents, which are the same or different, and are selected from the group consisting of halo, hydroxy, C1_8 alkoxy, -NH2, -C(0)NH2, -CH(O) ,
-C(0)0H, and -N02, X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from the group consisting of C1_8 lower alkyl, -C(0)CH3, and -C(0)NH2, and y is an integer from 1 to 3, consistent with the valence of X; and
R,R2N-N-0 (VIII)
II N-0R3 wherein R1 and R2 are independently chosen from C1-12 straight chain alkyl, Cx_12 alkoxy or acyloxy substituted straight chain alkyl, C2_12 hydroxy or halo substituted straight chain alkyl, C3_12 branched chain alkyl, C3_12 hydroxy, halo, alkoxy, or acyloxy substituted branched chain alkyl, a C3_12 straight or branched chain olefinic unsubstituted or substituted with hydroxy, alkoxy, acyloxy, halo or benzyl, or Rx and R2 together with the nitrogen atom to which they are bonded form a heterocyclic group, and R3 is a group selected from C1_12 straight chain and C3_1 branched chain alkyl which are unsubstituted or substituted by hydroxy, halo, acyloxy or alkoxy, C2_12 straight chain or C3_12 branched chain olefinic which are unsubstituted or substituted by halo, alkoxy, acyloxy or hydroxy, C1-12 unsubstituted or substituted acyl, sulfonyl and carboxamido; or R3 is a group of the formula -(CH2)n-0N=N(0)NR-^Rj, wherein n is an integer of 2-8, and R-*^ and R2 are as defined above.
14. The method of claim 13, wherein said compound comprising a nitric oxide-releasing [N202] functional group is a compound of formula III, and B is the substituted piperazine moiety
—N N-N202 ".
15. The method of claim 13, wherein said compound comprising a nitric oxide-releasing [N 02] functional group is a compound of formula V, and R1 and R2 are selected so that Rλ and R2, together with the nitrogen atom to which they are bonded, form a heterocyclic group.0
16. The method of claim 15, wherein the heterocyclic group is selected from the group consisting of pyrrolidino, piperidino, piperazino and morpholino.
17. The method of claim 13, wherein said compound comprising a nitric oxide-releasing [N202] functional group is a compound of formula VIII, and the heterocyclic group is selected from the group consisting of pyrrolidino, piperidino, piperazino, and morpholino.
18. The method of claim 12, wherein the moiety X of said functional group is part of the polymeric backbone.
19. The method of claim 12, wherein the moiety X of said functional group is part of a group pendant to the polymeric backbone.
20. The method of claim 12, wherein the biopolymer is selected from the group consisting of a peptide, a protein, and a nucleic acid.
21. The method of claim 20, wherein the protein is an antibody and the nucleic acid is an oligonucleotide.
22. The method of claim 12, wherein said polymer is biodegradable.
23. The method of claim 1, wherein said nitric oxide delivery means is selected from the group consisting of a transurethral applicator, a penile implant, a drug pump, a catheter, a self-adhering means, a liposome, a microparticle, a microsphere, a bead, a disk, a dermal patch and a condom.
24. A nitric oxide delivery means for the treatment of impotency in a male animal, said nitric oxide delivery means being selected from the group consisting of a transurethral applicator, a penile implant, a dermal patch and a condom, said nitric oxide delivery means comprising a compound or a polymer, wherein each of said compound and said polymer comprises a nitric oxide-releasing functional group selected from the group consisting of X-f-N(0)N0] and [N(0)NO-}-X, wherein X is a moiety bonded to said -£-N(0)NO] or [N(0)NO-3-, and wherein the -f-N(0)N0] or [N(0)N -}- group is covalentiy bonded in said polymer through said moiety X, said delivery means being capable of locally releasing a penile erection-inducing amount of nitric oxide to the penis of an impotent male animal.
25. The nitric oxide delivery means of claim 24, wherein said nitric oxide-releasing N202 functional group is from a compound of the formula selected from the group consisting of I, II, III, IV, V, VI, VII and VIII as follows:
Figure imgf000041_0001
wherein J is an organic or inorganic moiety, M x is a pharmaceutically acceptable cation, where x is the valence of the cation, a is 1 or 2, and b and c are the smallest integers that result in a neutral compound;
R1-NH+-(CH2)χ-N-[(CH2)yN]d-[(CH2)2-N]b-R3 (II)
N202
wherein b and d are the same or different and are zero or one, Rl t R , R3, R4, and R5 are the same or different and are hydrogen, C3_8 cycloalkyl, C1_12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, and x, y, and z are the same or different and are integers from 2 to 12; (III)
R-,
wherein B is or -N N-N202 "
Figure imgf000042_0001
R6 and R7 are the same or different and are hydrogen, c 3-β cycloalkyl, C1_12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2 ,2, 2-trichloro- t-butoxycarbonyl, f is an integer from 0 to 12, with the proviso that when B is the substituted piperazine moiety
—N N-N202~
then f is an integer from 2 to 12;
Figure imgf000042_0002
wherein R8 is hydrogen, C3_8 cycloalkyl, c1_12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-tri-chloro-t-butoxycarbonyl, R9 is hydrogen or a C1-C12 straight or branched chain alkyl, and g is 2 to 6;
Figure imgf000042_0003
wherein Rx and R2 are independently selected from the group consisting of a C1-C12 straight or branched chain alkyl and benzyl, M+x is a pharmaceutically acceptable cation, and x is the valence of the cation;
K[(M)x χ '(L)y(R1R2N-N202)z] (VI)
wherein M is a pharmaceutically acceptable metal, or where x is at least two, a mixture of two different pharmaceutically acceptable metals, L is a ligand different from (R1R2N-N202) and is bound to at least one metal, R1 and R2 are each organic moieties and are the same or different, x is an integer of from 1 to 10, x' is the formal oxidation state of the metal M, and is an integer of from 1 to 6, y is an integer of from 1 to 18, with the proviso that y is at least 2, the ligands L are the same or different, z is an integer from 1 to 20, and K is a pharmaceutically acceptable counterion to render the compound neutral to the extent necessary;
[R-N(H)N(N0)0-]yX (VII)
wherein R is C2_8 lower alkyl, phenyl, benzyl, or C3_8 cycloalkyl, any of which R groups can be substituted by one to three substituents, which are the same or different, and are selected from the group consisting of halo, hydroxy, C*^ alkoxy, -NH2, -C(0)NH2, -CH(O) , -C(0)OH, and -N02, X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from the group consisting of C1_8 lower alkyl, -C(0)CH3, and -C(0)NH2, and y is an integer from 1 to 3, consistent with the valence of X; and
Figure imgf000043_0001
wherein Rj and R2 are independently chosen from C^-^ straight chain alkyl, C1_12 alkoxy or acyloxy substituted straight chain alkyl, C2_12 hydroxy or halo substituted straight chain alkyl, C3_12 branched chain alkyl, C3_12 hydroxy, halo, alkoxy, or acyloxy substituted branched chain alkyl, a C3_12 straight or branched chain olefinic unsubstituted or substituted with hydroxy, alkoxy, acyloxy, halo or benzyl, or Rx and R2 together with the nitrogen atom to which they are bonded form a heterocyclic group, and R3 is a group selected from C1_12 straight chain and C3_12 branched chain alkyl which are unsubstituted or substituted by hydroxy, halo, acyloxy or alkoxy, C2_12 straight chain or C3_12 branched chain olefinic which are unsubstituted or substituted by halo, alkoxy, acyloxy or hydroxy, C1_12 unsubstituted or substituted acyl, sulfonyl and carboxamido; or R3 is a group of the formula -(CH2)n-0N=N(0)NR1R2, wherein n is an integer of 2-8, and R1 and R2 are as defined above.
26. The nitric oxide delivery means of claim 25, wherein, when said nitric oxide-releasing [N202] functional group is from a compound of formula III, and B is the substituted piperazine moiety
—N N- 202 "
27. The nitric oxide delivery means of claim 25, wherein, said nitric oxide-releasing [N202] functional group is from a compound of formula V, and Rχ and R2 are selected so that Rχ and R2, together with the nitrogen atom to which they are bonded, form a heterocyclic group.
28. The nitric oxide delivery means of claim 27, wherein the heterocyclic group is selected from the group consisting of pyrrolidino, piperidino, piperazino and morpholino.
29. The nitric oxide delivery means of claim 25, wherein said nitric oxide-releasing [N202] functional group is from a compound of formula VIII, and the heterocyclic group is selected from the group consisting of pyrrolidino, piperidino, piperazino and morpholino.
30. The nitric oxide delivery means of claim 24, wherein the moiety X of said functional group is part of the polymeric backbone.
31. The nitric oxide delivery means of claim 24, wherein the moiety X of said functional group is part of a group pendant to the polymeric backbone.
32. The nitric oxide delivery means of claim 32, wherein the polymer is selected from the group consisting of polyolefins, polyethers, polyesters, polyamides, polyurethanes, and biopolymers.
33. The nitric oxide delivery means of claim 24, wherein the biopolymer is selected from the group consisting of a peptide, a protein, and a nucleic acid.
34. A nitric oxide delivery means for the treatment of impotency in a male animal, said nitric oxide delivery means being selected from the group consisting of a transurethral applicator, a penile implant, a dermal patch and a condom, said nitric oxide delivery means comprising a coprecipitation product of a polymer selected from the group consisting of a polyolefin, a polyether, a polyester, a polyamide, a polyurethane and a biopolymer, and a compound comprising a nitric oxide-releasing [N202] functional group.
35. The nitric oxide delivery means of claim 34, wherein said nitric oxide-releasing [N202] functional group is from a compound of the formula selected from the group consisting of I, II, III, IV, V, VI, vii and VIII as follows:
Figure imgf000046_0001
wherein J is an organic or inorganic moiety, M x is a pharmaceutically acceptable cation, where x is the valence of the cation, a is 1 or 2, and b and c are the smallest integers that result in a neutral compound;
R1-NH+-(CH2)χ-N-[(CH2)yN]d-[(CH2)z-N]b-R3 (II) R2 N2°2~ R5 R4
wherein b and d are the same or different and are zero or one, l t R2, R3, R4, and R5 are the same or different and are hydrogen, C3_8 cycloalkyl, C1_12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, and x, y, and z are the same or different and are integers from 2 to 12;
Figure imgf000046_0002
wherein B is or —N N-N202 "
Figure imgf000046_0003
R6 and R7 are the same or different and are hydrogen, C3_8 cycloalkyl, C1_12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-trichloro- t-butoxycarbonyl, f is an integer from 0 to 12, with the proviso that when B is the substituted piperazine moiety then f is an integer from 2 to 12;
Figure imgf000047_0001
wherein R8 is hydrogen, C3_8 cycloalkyl, C1_12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-tri-chloro-t-butoxycarbonyl, R9 is hydrogen or a ι"ci2 straight or branched chain alkyl, and g is 2 to 6;
Figure imgf000047_0002
wherein R and R2 are independently selected from the group consisting of a C1-C12 straight or branched chain alkyl and benzyl, M+x is a pharmaceutically acceptable cation, and x is the valence of the cation;
K[(M)x'(L)v(R1R2N-N202)2] (VI)
wherein M is a pharmaceutically acceptable metal, or where x is at least two, a mixture of two different pharmaceutically acceptable metals, L is a ligand different from (R1R2N-N202) and is bound to at least one metal, R1 and R2 are each organic moieties and are the same or different, x is an integer of from l to 10, x' is the formal oxidation state of the metal M, and is an integer of from 1 to 6, y is an integer of from 1 to 18, with the proviso that y is at least 2, the ligands L are the same or different, z is an integer from 1 to 20, and K is a pharmaceutically acceptable counterion to render the compound neutral to the extent necessary;
[R-N(H)N(N0)0-]yX (VII)
wherein R is C2.8 lower alkyl, phenyl, benzyl, or C3_8 cycloalkyl, any of which R groups can be substituted by one to three substituents, which are the same or different, and are selected from the group consisting of halo, hydroxy, C*^ alkoxy, -NH2, -C(0)NH2, -CH(O) , -C(0)OH, and -N02, X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from the group consisting of C1_8 lower alkyl, -C(0)CH3, and -C(0)NH2, and y is an integer from 1 to 3, consistent with the valence of X; and
Figure imgf000048_0001
wherein R-^ and R are independently chosen from C1_1 straight chain alkyl, C1-12 alkoxy or acyloxy substituted straight chain alkyl, C2_12 hydroxy or halo substituted straight chain alkyl, C3_12 branched chain alkyl, C3_12 hydroxy, halo, alkoxy, or acyloxy substituted branched chain alkyl, a C3_12 straight or branched chain olefinic unsubstituted or substituted with hydroxy, alkoxy, acyloxy, halo or benzyl, or and R2 together with the nitrogen atom to which they are bonded form a heterocyclic group, and R3 is a group selected from C1_12 straight chain and C3_12 branched chain alkyl which are unsubstituted or substituted by hydroxy, halo, acyloxy or alkoxy, C2_12 straight chain or C3_12 branched chain olefinic which are unsubstituted or substituted by halo, alkoxy, acyloxy or hydroxy, Cλ_12 unsubstituted or substituted acyl, sulfonyl and carboxamido; or R3 is a group of the formula -(CH2)n-ON=N(0)NR1R2, wherein n is an integer of 2-8, and R: and R2 are as defined above.
36. The nitric oxide delivery means of claim 35, wherein, when said nitric oxide-releasing [N202] functional group is from a compound of formula III, B is the substituted piperazine moiety
—N N-N202 "
37. The nitric oxide delivery means of claim 35, wherein, when said nitric oxide-releasing [N202] functional group is from a compound of formula V, Rλ and R2 are selected so that Rχ and R2, together with the nitrogen atom to which they are bonded, form a heterocyclic group.
38. The nitric oxide delivery means of claim 37, wherein the heterocyclic group is selected from the group consisting of pyrrolidino, piperidino, piperazino and morpholino.
39. The nitric oxide delivery means of claim 35, wherein, when said nitric oxide-releasing [N202] functional group is from a compound of formula VIII, the heterocyclic group is selected from the group consisting of pyrrolidino, piperidino, piperazino, and morpholino.
40. The nitric oxide delivery means of claim 34, wherein the biopolymer is selected from the group consisting of a peptide, a protein, and a nucleic acid.
PCT/US1996/004889 1995-04-10 1996-04-10 Use of nitric oxide-releasing agents to treat impotency WO1996032118A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL96322742A PL322742A1 (en) 1995-04-10 1996-04-10 Application of nitrogen oxide releasing agents in treading impotency
JP8531124A JPH11508872A (en) 1995-04-10 1996-04-10 Use of nitric oxide releasing drugs to treat impotence
EP96911665A EP0820294A1 (en) 1995-04-10 1996-04-10 Use of nitric oxide-releasing agents to treat impotency
AU54480/96A AU5448096A (en) 1995-04-10 1996-04-10 Use of nitric oxide-releasing agents to treat impotency
NO974680A NO974680L (en) 1995-04-10 1997-10-10 Use of agents which release nitrogen-containing oxide for the treatment of impotence

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/419,044 US5910316A (en) 1992-08-24 1995-04-10 Use of nitric oxide-releasing agents to treat impotency
US08/419,044 1995-04-10

Publications (1)

Publication Number Publication Date
WO1996032118A1 true WO1996032118A1 (en) 1996-10-17

Family

ID=23660566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/004889 WO1996032118A1 (en) 1995-04-10 1996-04-10 Use of nitric oxide-releasing agents to treat impotency

Country Status (11)

Country Link
US (2) US5910316A (en)
EP (1) EP0820294A1 (en)
JP (1) JPH11508872A (en)
KR (1) KR19980703796A (en)
AU (1) AU5448096A (en)
CA (1) CA2217863A1 (en)
CZ (1) CZ320497A3 (en)
HU (1) HUP9801591A3 (en)
NO (1) NO974680L (en)
PL (1) PL322742A1 (en)
WO (1) WO1996032118A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2774594A1 (en) * 1998-02-12 1999-08-13 Philippe Gorny Use of a combination for treating e.g. lack of sexual desire, failure to reach orgasm or decrease or absence of vaginal lubrication
EP1018879A1 (en) * 1996-02-02 2000-07-19 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
JP2002505676A (en) * 1997-06-23 2002-02-19 クイーンズ ユニバーシティー アット キングストン Microdose therapy
US6747063B2 (en) 1996-04-23 2004-06-08 Cellegy Pharmaceuticals, Inc. Combination therapy for treatment of erectile dysfunction
WO2006128742A2 (en) * 2005-06-01 2006-12-07 Nolabs Ab Treatment and pre-treatment device, and manufacturing method therefor, involving nitric oxide
EP1731176A1 (en) * 2005-06-01 2006-12-13 NOLabs AB Pre-treatment device comprising nitric oxide
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US6323211B1 (en) * 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
CA2650204A1 (en) 1996-12-31 1998-07-09 Harry B. Demopoulos Pharmaceutical preparations of glutathione and methods of administration thereof
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US20040043068A1 (en) * 1998-09-29 2004-03-04 Eugene Tedeschi Uses for medical devices having a lubricious, nitric oxide-releasing coating
US20040151785A1 (en) * 1998-10-06 2004-08-05 Diamedica Inc. Method for treating insulin resistance through hepatic nitric oxide
CA2381095C (en) * 1998-10-06 2012-08-14 The University Of Manitoba Method for treating insulin resistance through hepatic nitric oxide
FR2786699B1 (en) * 1998-12-02 2002-10-04 Philippe Gorny MEDICINE, IN PARTICULAR FOR PREVENTING OR TREATING SEXUAL DYSFUNCTIONS
CA2353531A1 (en) * 1999-09-02 2001-03-08 Rice University Nitric oxide-producing hydrogel materials
US7279176B1 (en) 1999-09-02 2007-10-09 Rice University Nitric oxide-producing hydrogel materials
US7052711B2 (en) * 1999-09-02 2006-05-30 Rice University Nitric oxide-producing hydrogel materials
US6270779B1 (en) * 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
EA005649B1 (en) 2000-08-11 2005-04-28 Дэвид Р. Уитлок Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
US9080146B2 (en) 2001-01-11 2015-07-14 Celonova Biosciences, Inc. Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface
US6899703B2 (en) * 2001-03-13 2005-05-31 Clemson University Intraurethral device for treating or detecting various diseases or infections of the urinary system
US6558312B2 (en) 2001-03-13 2003-05-06 Clemson University Intraurethral device for incontinence
EP1406608B1 (en) 2001-05-02 2009-07-29 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
US6867194B2 (en) 2001-08-09 2005-03-15 Wayne State University Enzyme activated nitric oxide donors
EP1436018A1 (en) * 2001-09-26 2004-07-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Nitric oxide-releasing coated medical devices and method of preparing same
US6703046B2 (en) 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
BR0306868A (en) * 2002-01-11 2005-04-12 David R Whitlock Compositions including ammonia oxidizing bacteria and methods for using them
CA2480033C (en) * 2002-03-21 2011-05-10 The University Of Utah Research Foundation In vivo use of glutathionone s-transferase activated nitric oxide donors
AU2003234510A1 (en) * 2002-05-07 2003-11-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
WO2003095623A2 (en) * 2002-05-10 2003-11-20 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
DK1505871T3 (en) * 2002-05-10 2013-05-13 Univ Miami Conservation of RNA and Morphology in Cells and Tissues
JP2007502831A (en) * 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US20070238740A1 (en) * 2003-08-28 2007-10-11 Nitromed, Inc. Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
CA2539974A1 (en) * 2003-09-26 2005-04-07 David R. Whitlock Methods of using ammonia oxidizing bacteria
US20090131342A1 (en) * 2004-01-22 2009-05-21 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
US7569559B2 (en) * 2004-02-09 2009-08-04 Noxilizer, Inc. Nitric oxide-releasing molecules
US7829553B2 (en) * 2004-02-09 2010-11-09 Amulet Pharmaceuticals, Inc. Nitric oxide-releasing polymers
AU2005289414B2 (en) 2004-09-27 2010-12-09 Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers, and compositions, medical devices, and uses thereof
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
EP1814535A4 (en) * 2004-11-08 2008-06-04 Nitromed Inc Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
EP1757278A1 (en) * 2005-08-23 2007-02-28 NOLabs AB Device, system, and method comprising microencapsulated liquid for release of nitric oxide from a polymer
US20060188528A1 (en) * 2005-02-23 2006-08-24 Ansell Healthcare Products Llc Spreadable warming lubricant
US7709428B2 (en) * 2005-02-23 2010-05-04 Ansell Healthcare Products Llc Thickened spreadable warming lubricant
EP1858863A1 (en) * 2005-02-28 2007-11-28 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
US20090215838A1 (en) * 2005-03-09 2009-08-27 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
WO2006100154A1 (en) 2005-03-24 2006-09-28 Nolabs Ab Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
EP1704876A1 (en) * 2005-03-24 2006-09-27 NOLabs AB Cosmetic treatment, device for performing said treatment and manufacturing method thereof
EP1865770A4 (en) * 2005-04-07 2010-12-29 Nitromed Inc The genetic risk assessment in heart failure: impact of the genetic variation of nos3
EP1883614A4 (en) * 2005-05-23 2010-04-14 Nicox Sa Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
JP2009511087A (en) * 2005-06-20 2009-03-19 アビームーア メディカル インコーポレイテッド Drug delivery products, accessories, and systems
EP1915157A4 (en) * 2005-08-02 2010-09-01 Nicox Sa Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
WO2007024501A2 (en) * 2005-08-25 2007-03-01 Medtronic Vascular, Inc. Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
EP1945030A4 (en) * 2005-10-04 2009-10-21 Nitromed Inc The genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism
US7928079B2 (en) * 2005-10-31 2011-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
WO2007059311A2 (en) * 2005-11-16 2007-05-24 Nitromed, Inc. Furoxan compounds, compositions and methods of use
EP1968615A4 (en) * 2005-12-06 2010-08-04 Amulet Pharmaceuticals Inc Nitric oxide-releasing polymers
EP1968584A2 (en) * 2005-12-20 2008-09-17 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
CA2647859C (en) 2006-03-29 2016-01-05 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US8642093B2 (en) * 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US20090112197A1 (en) * 2007-10-30 2009-04-30 Searete Llc Devices configured to facilitate release of nitric oxide
US8221690B2 (en) * 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US20110190604A1 (en) * 2006-12-22 2011-08-04 Hyde Roderick A Nitric oxide sensors and systems
US7862598B2 (en) * 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US8770201B2 (en) * 2007-10-26 2014-07-08 Glycobiosciences Inc. Condom with multifunctional coating
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US20090112055A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Sleeves configured to facilitate release of nitric oxide
US8349262B2 (en) * 2007-10-30 2013-01-08 The Invention Science Fund I, Llc Nitric oxide permeable housings
US8877508B2 (en) * 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
CN102014870A (en) 2008-03-07 2011-04-13 犹他州大学研究基金会 Activated nitric oxide donors and methods of making and using thereof
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8425837B2 (en) 2009-02-23 2013-04-23 Noxilizer, Inc. Device and method for gas sterilization
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
AR077041A1 (en) 2009-06-09 2011-07-27 Prolong Pharmaceuticals Inc HEMOGLOBIN COMPOSITIONS. METHODS
EP2485734B1 (en) 2009-10-09 2014-07-02 Merck Sharp & Dohme Corp. Diuretics
US20110139163A1 (en) * 2009-12-15 2011-06-16 Hillila David J Vibration apparatus for stimulating paranasal sinuses
KR101024434B1 (en) * 2009-12-18 2011-03-23 구인옥 Support-device to improve impotence
US9265750B1 (en) 2010-02-22 2016-02-23 Gene C. Benckini Apparatus and method for correction of erectile dysfunction
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
BR112012033341B1 (en) 2010-06-30 2022-08-23 Cyclerion Therapeutics, Inc SGC STIMULATORS
NZ609955A (en) 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
ES2804263T3 (en) 2011-07-05 2021-02-05 Novan Inc Topical compositions
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
DK2854841T3 (en) 2012-06-04 2017-05-22 Diamedica Inc Kallikrein-1-glycosylation isoforms of human tissue
CN103690490B (en) * 2012-08-23 2017-11-17 尼奥克斯(文莱)控股有限公司 Nitric oxide production system and method are produced based on microencapsulated chemical agent delay
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
HUE059178T2 (en) 2013-03-15 2022-10-28 Cyclerion Therapeutics Inc Sgc stimulators
ES2836132T3 (en) 2013-08-08 2021-06-24 Novan Inc Topical compositions and methods of using them
WO2015089182A1 (en) 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
AU2015247710B2 (en) 2014-04-15 2021-09-09 Aobiome Llc Ammonia-oxidizing Nitrosomonas eutropha strain D23
CN105813617B (en) 2014-08-08 2021-05-28 诺万公司 Topical compositions and methods of using the same
EP3194382B1 (en) 2014-09-17 2021-09-08 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sgc stimulators
MX2017003518A (en) 2014-09-17 2017-07-28 Ironwood Pharmaceuticals Inc Sgc stimulators.
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
WO2017151905A1 (en) 2016-03-02 2017-09-08 Novan, Inc. Compositions for treating inflammation and methods of treating the same
CN109310630A (en) 2016-04-13 2019-02-05 诺万公司 For treating composition, system, kit and the method for infection
KR20230074840A (en) 2016-07-07 2023-05-31 사이클리온 테라퓨틱스, 인크. Solid forms of an sgc stimulator
CN109476686B (en) 2016-07-07 2022-01-18 赛克里翁治疗有限公司 Phosphorus prodrugs of sGC stimulators
US11186681B2 (en) 2016-10-07 2021-11-30 The University Of North Carolina At Chapel Hill S-Nitrosothiol-mediated hyperbranched polyesters
EP3565848A4 (en) 2017-01-03 2020-09-02 The University of North Carolina at Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
AU2018230478A1 (en) 2017-03-09 2019-09-12 Diamedica Inc. Dosage forms of tissue kallikrein 1
AU2018247167A1 (en) 2017-03-28 2019-09-26 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
CA3091458A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
KR102088809B1 (en) * 2018-06-20 2020-03-13 연세대학교 산학협력단 A nitric oxide carrier and a method for manufacturing the same
CA3124673A1 (en) 2018-12-28 2020-07-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto
US20230337678A1 (en) 2020-02-07 2023-10-26 Know Bio, Llc Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015779A1 (en) * 1992-02-07 1993-08-19 Anthony Ernest Bolton Method of increasing the concentration of nitric oxide in blood
CA2106105A1 (en) * 1993-09-14 1995-03-15 Larry K. Keefer Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5405919A (en) * 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
WO1995024898A1 (en) * 1994-03-17 1995-09-21 Comedicus, Incorporated Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE211789C (en)
US3153094A (en) * 1959-06-10 1964-10-13 Du Pont Nitrosamine manufacture
NL145762B (en) * 1970-05-27 1975-05-15 Sandoz Ag PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATION WITH HYPOTENSIVE / ANTIHYPERTENSIVE ACTION AND FORMED PREPARATION.
US3826832A (en) * 1970-06-08 1974-07-30 Sandoz Ag N-substituted amino-n-nitro-amino-acetonitriles as anti-anginal agents
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4265714A (en) * 1980-03-24 1981-05-05 General Electric Company Gas sensing and measuring device and process using catalytic graphite sensing electrode
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
DD211789A1 (en) * 1982-08-25 1984-07-25 Adw Ddr PROCESS FOR PREPARING POLYHYDROXYPOLYMER ESTERS, ESPECIALLY CELLULOSE ESTERS
US4638079A (en) * 1985-01-17 1987-01-20 Mallinckrodt, Inc. Inhibiting polymerization of ethylenically unsaturated monomers
US4708854A (en) * 1986-03-10 1987-11-24 The Dow Chemical Company Process for the removal of NO from fluid streams using a water-soluble polymeric chelate of a polyvalent metal
US4829991A (en) * 1987-01-06 1989-05-16 Medical Engineering Corp. Method and device for stimulating an erection
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
JPS63260971A (en) * 1987-04-20 1988-10-27 Hitachi Chem Co Ltd Radiation-curable pressure-sensitive adhesive composition
US4952289A (en) * 1988-05-09 1990-08-28 Aquanautics Corporation Macrocyclic amine complexes for ligand extraction and generation
US5094815A (en) * 1988-05-18 1992-03-10 Cornell Research Foundation, Inc. Photolytic interface for HPLC-chemiluminescence detection of non volatile N-nitroso compounds
US5025001A (en) * 1988-06-15 1991-06-18 Brigham And Women's Hospital S-nitroso derivatives of ACE inhibitors and the use thereof
SE463851B (en) * 1988-09-02 1991-02-04 Amsu Ltd COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA
US4954526A (en) * 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
US4921683A (en) * 1989-06-20 1990-05-01 The Dow Chemical Company Nitric oxide abatement with polymeric cobalt(III) chelates
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
FR2653337B1 (en) * 1989-10-23 1992-02-07 Dow Corning Sa SUSTAINED RELEASE ELEMENT AND METHOD FOR MANUFACTURING THE SAME.
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5087671A (en) * 1990-06-25 1992-02-11 The Curators Of The University Of Missouri Polymers for scavenging nitrosating agents
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
US5087631A (en) * 1990-12-18 1992-02-11 Glaxo Inc. Oxathi(SIV)azol-5-one compounds
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
JPH06506690A (en) * 1991-04-19 1994-07-28 ザ チルドレンズメディカルセンター コーポレーション Methods for blocking neuronal damage mediated by NMDA receptor complexes
DE69223157T2 (en) * 1991-09-24 1998-06-10 Us Health OXYGEN-SUBSTITUTED DERIVATIVES OF NUCLEOPHIL NITROGEN OXIDE ADDUCTS AND THEIR USE AS NITROGEN OXIDE DONOR PRODRUGS
US5389675A (en) * 1992-03-27 1995-02-14 The United States Of America As Represented By The Department Of Health And Human Services Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents
WO1993020806A1 (en) * 1992-04-13 1993-10-28 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide/nucleophile complexes for the treatment of cancer
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5427797A (en) * 1993-04-06 1995-06-27 Brigham And Women's Hospital Systemic effects of nitric oxide inhalation
ATE194769T1 (en) * 1993-10-08 2000-08-15 Us Health USE OF NITROGEN OXIDE RELEASING COMPOUNDS AS MEDICINAL AGENTS FOR RADIATION SENSITIZATION FOR HYPOXIC CELLS
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015779A1 (en) * 1992-02-07 1993-08-19 Anthony Ernest Bolton Method of increasing the concentration of nitric oxide in blood
US5405919A (en) * 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
CA2106105A1 (en) * 1993-09-14 1995-03-15 Larry K. Keefer Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
WO1995024898A1 (en) * 1994-03-17 1995-09-21 Comedicus, Incorporated Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1018879A1 (en) * 1996-02-02 2000-07-19 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
EP1018879A4 (en) * 1996-02-02 2002-07-24 Nitromed Inc Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6747063B2 (en) 1996-04-23 2004-06-08 Cellegy Pharmaceuticals, Inc. Combination therapy for treatment of erectile dysfunction
JP2002505676A (en) * 1997-06-23 2002-02-19 クイーンズ ユニバーシティー アット キングストン Microdose therapy
FR2774594A1 (en) * 1998-02-12 1999-08-13 Philippe Gorny Use of a combination for treating e.g. lack of sexual desire, failure to reach orgasm or decrease or absence of vaginal lubrication
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US9403852B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8962029B2 (en) 2005-05-27 2015-02-24 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US11691995B2 (en) 2005-05-27 2023-07-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9403851B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8956658B2 (en) 2005-05-27 2015-02-17 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
WO2006128742A2 (en) * 2005-06-01 2006-12-07 Nolabs Ab Treatment and pre-treatment device, and manufacturing method therefor, involving nitric oxide
EP1731176A1 (en) * 2005-06-01 2006-12-13 NOLabs AB Pre-treatment device comprising nitric oxide
WO2006128742A3 (en) * 2005-06-01 2007-04-05 Nolabs Ab Treatment and pre-treatment device, and manufacturing method therefor, involving nitric oxide
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US9737561B2 (en) 2009-08-21 2017-08-22 Novan, Inc. Topical gels and methods of using the same
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US10376538B2 (en) 2009-08-21 2019-08-13 Novan, Inc. Topical gels and methods of using the same
US11583608B2 (en) 2009-08-21 2023-02-21 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same
US9713652B2 (en) 2011-02-28 2017-07-25 The University Of North Carolina At Chapel Hill Nitric oxide-releasing S-nitrosothiol-modified silica particles and methods of making the same

Also Published As

Publication number Publication date
US5910316A (en) 1999-06-08
AU5448096A (en) 1996-10-30
JPH11508872A (en) 1999-08-03
HUP9801591A2 (en) 1999-02-01
EP0820294A1 (en) 1998-01-28
PL322742A1 (en) 1998-02-16
US6290981B1 (en) 2001-09-18
CA2217863A1 (en) 1996-10-17
HUP9801591A3 (en) 2000-06-28
NO974680D0 (en) 1997-10-10
CZ320497A3 (en) 1998-05-13
NO974680L (en) 1997-12-03
KR19980703796A (en) 1998-12-05

Similar Documents

Publication Publication Date Title
US6290981B1 (en) Use of nitric oxide-releasing agents to treat impotency
US5676963A (en) Implants, prostheses, and stents comprising polymer-bound nitric oxide/nucleophile adducts capable of releasing nitric oxide
EP0793500B1 (en) Pharmaceutical compositions comprising nitric oxide-releasing polysaccharides
US5525357A (en) Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US6379660B1 (en) Nitric oxide-releasing 1-[(2-carboxylato)pyrrolidin-1-yl] diazen-1-ium-1,2-diolates and composition comprising same
AU698525B2 (en) Use of nitric oxide-releasing polymers to treat restenosis and related disorders
CA2205555C (en) Use of nitric oxide-releasing agents for reducing metastasis risk
CA2216696C (en) Polysaccharide-bound nitric oxide-nucleophile adducts
US6703046B2 (en) Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
CA2106105C (en) Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
CA2205564C (en) Pharmaceutical compositions comprising nitric oxide-releasing biopolymers
CN1187771A (en) Use of nitric oxide-releasing agents to treat imptotency
AU695579C (en) Polysaccharide-bound nitric oxide-nucleophile adducts

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96194362.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2217863

Country of ref document: CA

Ref document number: 2217863

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1997-3204

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 1996 9024

Country of ref document: AT

Date of ref document: 19961017

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 19969024

Country of ref document: AT

Ref document number: 1019970707196

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1996 531124

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996911665

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996911665

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1997-3204

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019970707196

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996911665

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1997-3204

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1019970707196

Country of ref document: KR